This is an extract showing that fluorides are pharmacological chemicals.

POISONS STANDARD 2009

The National Drugs and Poisons Schedule Committee, acting in accordance with its power under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989* (the Act), prepares this new Poisons Standard under that Act, in substitution for the current Poisons Standard.

Signed

DR RUTH LOPERT CHAIR
NATIONAL DRUGS AND POISONS SCHEDULE COMMITTEE

Dated this 3rd day of August 2009

Schedule 1-Standard for the Uniform Scheduling of Drugs and Poisons No. 23 published by the National Drugs and Poisons Scheduling Committee in 2009

SCHEDULE 1

This Schedule is intentionally blank.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 2

(Substances marked † are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH_3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a)in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b)in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing

10 per cent or less of total local anaesthetic substances, **except** in dermal

preparations containing 2 per cent or less of total local anaesthetic substances.
AMOROLFINE for topical use in preparations containing 0.25 per cent or less of amorolfine **except** in preparations for the treatment of tinea pedis.
ANTAZOLINE in eye drops.
ASPIRIN **except**:
(a)when included in Schedule 4, 5 or 6;
(b)in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:
(i)enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and
(ii)compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
(i)packed in blister or strip packaging or in a container with a child- resistant closure;

SCHEDULE 2–continued
(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325 mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and
(iii)compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(d)in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:
(i)packed in blister or strip packaging or in a container with a child- resistant closure;
(ii)in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and
(iii)compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.
ATROPA BELLADONNA (belladonna):
(a)for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
(b)for oral use:
(i)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ATROPINE (excluding atropine methonitrate) for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total

solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

SCHEDULE 2–continued

(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE in preparations for nasal use.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing
200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a)containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b)in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a)in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(b)in preparations for the treatment of tinea pedis.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

SCHEDULE 2–continued

(b)in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no

greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.
CARBOCISTEINE.
CETIRIZINE in preparations for oral use.
CHLOPHEDIANOL.
CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.
CHLOROFORM in preparations for therapeutic use **except**:
(a)when included in Schedule 4; or
(b)in preparations containing 0.5 per cent or less of chloroform.
CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b)in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
CICLOPIROX in preparations for dermal use and for application to the nails containing 2 per cent or less of ciclopirox **except** in preparations for the treatment of tinea pedis.

SCHEDULE 2–continued

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.
CINNAMEDRINE.
CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.
CODEINE when:
(a)compounded:
(i)with a single non-opiate analgesic substance in tablets or capsules each containing 10 mg or less of codeine when:
(A)packed in blister or strip packaging or in a container with a child-resistant closure; and
(B)in a primary package containing 25 or less dosage units; or
(ii)with a single non-opiate analgesic substance in individually wrapped powders containing 10 mg or less of codeine when in a primary pack containing 25 or less dosage units; or
(iii)with one or more other therapeutically active substances:
(A)in divided preparations each containing 10 mg or less of codeine; or
(B)in undivided preparations containing 0.25 per cent or less of codeine; and
(b)labelled with a recommended daily dose not exceeding 60 mg of codeine.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.
DATURA spp. for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

SCHEDULE 2–continued
(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except when separately specified in these Schedules.
DATURA STRAMONIUM (stramonium) for oral use when:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DATURA TATULA (stramonium) for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except for smoking or burning.
DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of
Delphinium staphisagria.
DESLORATADINE in preparations for oral use.
DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b)in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.

SCHEDULE 2–continued

DEXTROMETHORPHAN(excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.
DIBROMOPROPAMIDINE for ophthalmic use.
DICLOFENAC in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac.
DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:
(a)containing 5 mg or less of dihydrocodeine per dosage unit;
(b)packed in blister or strip packaging or in a container with a child-resistant closure;
(c)enclosed in primary packs containing 25 or less dosage units; and
(d)labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.
DIMENHYDRINATE in primary packs of 10 doses or less, for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.
DIPHENHYDRAMINE in oral preparations:
(a)in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
(b)when combined with one or more other therapeutically active substances when:
(i)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii)in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:
(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

SCHEDULE 2–continued
(b)in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
DUBOISIA LEICHHARDTII for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(b)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.
ETAFEDRINE.
ETHER for therapeutic use **except**:
(a)when included in Schedule 4; or
(b)in preparations containing 10 per cent or less of ether.
ETHYLMORPHINE when:
(a)compounded with one or more other therapeutically active substances:
(i)in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

SCHEDULE 2–continued
(ii)in undivided preparations containing 0.25 per cent or less of ethylmorphine; and
(b)labelled with a recommended dose not exceeding 15 mg of ethylmorphine.
ETOFENAMATE in preparations for external use.
FAMOTIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.
FELBINAC in preparations for external use.
FEXOFENADINE in preparations for oral use.

FLUORIDES for human use:
(a) in preparations for ingestion containing 0.5 mg or less of **fluoride** ion per dosage unit; or
(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:
(i)for therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels* **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(ii)for non-therapeutic use when labelled with warnings to the following effect:
(A)Do not swallow; and
(B)Do not use [this product/name of product] in children six years of age or less,

except in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labeled with warnings to the following effect:
(A)Do not swallow; and
(B)Do not use [this product/name of product] in children six years of age or less,

SCHEDULE 2–continued

except in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.
FLURBIPROFEN in divided preparations for topical oral use containing 10 mg or less of flurbiprofen per dosage unit.
FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
FOLIC ACID for human therapeutic use **except**:
(a)when included in Schedule 4; or
(b)in preparations containing 500 micrograms or less of folic acid per recommended daily dose.
FOLINIC ACID for human therapeutic use **except**:
(a)when included in Schedule 4; or
(b)in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.
†FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:
(a)in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b)in other preparations containing 0.2 per cent or less of free formaldehyde.
GELSEMIUM SEMPERVIRENS.
GLUTARALDEHYDE for human therapeutic use.
HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:
(a)in preparations containing 0.75 per cent or less of hexachlorophane; or
(b)in preparations for use on infants, as specified in Schedule 4.

SCHEDULE 2–continued

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:
(a)for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal

substance; or
(b)for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
(i)in undivided preparations in packs of 35 g or less; or
(ii)in packs containing 12 or less suppositories.
HYDROQUINONE (excluding monobenzone and other alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except** hair preparations containing 1 per cent or less of hydroquinone.
8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.
HYOSCINE (excluding hyoscine butylbromide):
(a)for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
(b)for oral use:
(i)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

SCHEDULE 2–continued
HYOSCYAMINE:
(a)for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or
(b)for oral use:
(i)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
(ii)in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:
(a)in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b)in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,
except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:
(a)in liquid preparations when sold in the manufacturer's original pack containing 4 grams or less of ibuprofen; or
(b)in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:
(i)as the only therapeutically active constituent other than an effervescent agent;
(ii)packed in blister or strip packaging or in a container with a child- resistant closure;

SCHEDULE 2–continued
(iii)in a primary pack containing not more than 25 dosage units;
(iv)not labelled for the treatment of children 6 years of age or less; and
(v)compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.
INDANAZOLINE.
INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.
IODINE:
(a)in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or
(b)in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors).
IPRATROPIUM in preparations for nasal use.
IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:
(a)when included in Schedule 4; or
(b)when labelled with a recommended daily dose of 24 mg or less of iron:
(i)in undivided preparations supplied in packs each containing 750 mg or less of iron; or
(ii)in divided preparations:
(A)containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or
(B)containing 5 mg or less of iron per dosage unit.
ISOCONAZOLE for human use in dermal preparations.
ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

SCHEDULE 2–continued

KETOCONAZOLE in preparations for dermal use **except**:
(a)in preparations containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
(b)in preparations for the treatment of tinea pedis.
KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen. LEVOCABASTINE in topical eye or nasal preparations.
LIGNOCAINE in preparations for topical use other than eye drops:
(a)containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(b)in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.
LITHIUM in preparations for dermal use containing 1 per cent or less of lithium **except**:
(a)when present as an excipient at 0.25 per cent or less of lithium; or
(b)in preparations containing 0.01 per cent or less of lithium.
LOBELIA INFLATA **except** for smoking or burning.
LOBELINE **except** in preparations for smoking or burning.
LODOXAMIDE in preparations for ophthalmic use.
LOPERAMIDE in preparations for oral use in packs of 20 dosage units or less. LORATADINE in preparations for oral use.
MEBENDAZOLE for human therapeutic use.
MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

SCHEDULE 2–continued

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.
MEPYRAMINE for dermal use.
MERCURY for external use in preparations containing 0.5 per cent or less of mercury.
METHOXAMINE in preparations for external use **except** in preparations containing 1 per cent or less of methoxamine.
METHOXYPHENAMINE.
METHYLEPHEDRINE.
MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.
MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.
MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis

for up to six months in adults and children 12 years of age and over.
NAPHAZOLINE.
NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.
NICLOSAMIDE for human therapeutic use.
NICOTINE for use as an aid in withdrawal from tobacco smoking in preparations for inhalation.
NIZATIDINE when sold in the manufacturer's original pack containing not more than 14 days supply.
NOSCAPINE.
NYSTATIN in dermal preparations.
OXETACAINE (oxethazaine) in preparations for internal use.
OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.
OXYMETAZOLINE.
PAPAVERINE **except** when included in Schedule 4.

SCHEDULE 2–continued

PARACETAMOL for therapeutic use **except**:
(a)when included in Schedule 4;
(b)in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
(i)enclosed in a primary pack that contains not more than 12 such powders or sachets of granules;
(ii)compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(iii)not labelled for the treatment of children 6 years of age or less; and
(iv)not labelled for the treatment of children under 12 years of age when combined with phenylephrine; or
(c)in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine or when combined with effervescent agents) when:
(i)packed in blister or strip packaging or in a container with a child- resistant closure;
(ii)in a primary pack containing not more than 25 tablets or capsules;
(iii)compliant with the requirements of the Required Advisory Statements for Medicine Labels;
(iv)not labelled for the treatment of children 6 years of age or less; and
(v)not labelled for the treatment of children under 12 years of age when combined with phenylephrine.
†PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:
(a)in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or
(b)in other preparations containing 0.2 per cent or less of free formaldehyde.

SCHEDULE 2–continued

PENCICLOVIR for external use for the treatment of *Herpes labialis*.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a)in eye drops; or

(b)when combined with one or more other therapeutically active substances in oral preparations when:

(i)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii)in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

except in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a)when included in Schedule 4; or

(b)in preparations for external use containing 3 per cent or less of such substances.

PHENYLEPHRINE **except**:

(a)when included in Schedule 4;

(b)in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c)in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

(a)in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b)when compounded with one or more other therapeutically active substances, in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 2–continued

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.
PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
(a)in a primary pack containing ten dosage units or less, for the prevention or treatment of motion sickness; or
(b)when combined with one or more other therapeutically active substances when:
(i)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(ii)in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

SCHEDULE 2–continued

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.
RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days supply **except** in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer's original pack containing not more than 14 dosage units.
SALICYLAMIDE **except** when included in Schedule 4.
SELENIUM in preparations for human therapeutic use **except**:
(a)for topical use containing 3.5 per cent or less of selenium sulfide;
(b)when included in Schedule 4; or
(c)for oral use with a recommended daily dose of 150 micrograms or less.
SILVER for therapeutic use **except**:
(a)in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(b)in other preparations containing 1 per cent or less of silver.
SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use. SODIUM NITRITE for therapeutic use (excluding when present as an excipient). SQUILL **except** in preparations containing 1 per cent or less of squill. SULCONAZOLE in preparations for dermal use.
TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis. TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.
THIABENDAZOLE for human therapeutic use.
TIOCONAZOLE in preparations for dermal use **except** in preparations for the treatment of tinea pedis.

SCHEDULE 2–continued

TRAMAZOLINE.
TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.
TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:
(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b)in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:
(a)at least one of the other therapeutically active substances is a sympathomimetic decongestant; or
(b)in a day-night pack containing triprolidine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,
except in preparations for the treatment of children under 2 years of age.
TUAMINOHEPTANE.
TYMAZOLINE.
XYLOMETAZOLINE.
ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline.
ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.
AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.
AMOROLFINE for topical use **except**:
(a)when included in Schedule 2; or
(b)in preparations for the treatment of tinea pedis. AZATADINE in oral preparations.
AZELASTINE in topical eye preparations containing 0.05 per cent or

less of azelastine.

BROMPHENIRAMINE in oral preparations **except**:

(a)when included in Schedule 2; or

(b)for the treatment of children under 2 years of age. BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use. CHLORBUTOL in preparations for human use **except**:

(a)when included in Schedule 2; or

(b)in preparations containing 0.5 per cent or less of chlorbutol. CHLORPHENIRAMINE in oral preparations **except**:

(a)when included in Schedule 2; or

(b)for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a)when included in Schedule 2; or

(b)in preparations for the treatment of tinea pedis.

SCHEDULE 3–continued

CIMETIDINE in a primary pack containing not more than 14 days supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when compounded with:

(a)a single non-opiate analgesic substance in divided preparations containing 10 mg or less of codeine per dosage unit and with a recommended daily dose not exceeding 60 mg of codeine; or

(b)paracetamol in divided preparations containing 12 mg or less of codeine per dosage unit and with a recommended daily dose greater than 60 mg but not exceeding 100 mg of codeine when:

(i)packed in blister or strip packaging or in a container with a child- resistant closure; and

(ii)in a primary pack containing 12 or less dosage units,

except when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except**:

(a)when included in Schedule 2; or

(b)for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a)in divided preparations containing 10 mg or less per dosage unit and with a

recommended dose not exceeding 15 mg of dihydrocodeine; or

SCHEDULE 3–continued
(b)in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,
except when included in Schedule 2.
DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.
DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.
DIMETHINDENE in oral preparations.
DIPHENHYDRAMINE in oral preparations **except**:
(a)when included in Schedule 2; or
(b)for the treatment of children under 2 years of age.
DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.
DITHRANOL for therapeutic use.
DOXYLAMINE in oral preparations **except**:
(a)when included in Schedule 2; or
(b)for the treatment of children under 2 years of age. ECONAZOLE in preparations for vaginal use.
ERYTHRITYL TETRANITRATE for therapeutic use.
FLAVOXATE.
FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.
FLUORIDES for human topical use:
(a)in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

SCHEDULE 3–continued
(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:
(i)in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(ii)in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:
(A) Do not swallow; and
(B) Do not use [this product/name of product] in children six years of age or less; or
(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.
GLUCAGON.

GLYCERYL TRINITRATE:
(a) in preparations for oral use; or
(b)in preparations for rectal use. GLYCOPYRRONIUM **except** when included in Schedule 4.
HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:
(a)for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or
(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:
(i)in undivided preparations, in packs of 35 g or less; or
(ii)in packs containing 12 or less suppositories,
except when included in Schedule 2.

SCHEDULE 3–continued
IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen, in a primary pack containing not more than 50 dosage units when labelled:
(a)with a recommended daily dose of 1200 mg or less of ibuprofen; and
(b)not for the treatment of children under 12 years of age,
except when included in or expressly excluded from Schedule 2.
INOSITOL NICOTINATE.
ISOCONAZOLE in preparations for vaginal use.
ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.
KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.
LEVONORGESTREL for emergency post-coital contraception.
MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
MALATHION in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.
MANNITYL HEXANITRATE for therapeutic use.
MEPYRAMINE in oral preparations.
METHDILAZINE in oral preparations.
METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.
MICONAZOLE for human use in topical preparations:
(a)for the treatment of oral candidiasis; or
(b)for vaginal use.

SCHEDULE 3–continued
NICOTINIC ACID for human therapeutic use in divided preparations

containing 250 mg or less of nicotinic acid per dosage unit **except**:
(a)in preparations containing 100 mg or less of nicotinic acid per dosage unit; or
(b)nicotinamide.
NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.
NYSTATIN in preparations for topical use **except** when included in Schedule 2.
ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.
OXICONAZOLE in preparations for vaginal use.
PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days of supply.
PHENIRAMINE in oral preparations **except**:
(a)when included in Schedule 2; or
(b)for the treatment of children under 2 years of age.
PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
PROMETHAZINE in oral preparations **except**:
(a)when included in Schedule 2; or
(b)in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight- control purposes) when supplied in a primary pack:
(a)in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
(b)in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).
SALBUTAMOL as the only therapeutically active substance:
(a)in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
(b)in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.
SALICYLIC ACID in preparations for dermal use **except** in preparations

containing 40 per cent or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.
TERBUTALINE as the only therapeutically active substance:
(a)in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or
(b)in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.
THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.
TIOCONAZOLE in preparations for vaginal use.
TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

SCHEDULE 3–continued

TRIMEPRAZINE:
(a)in solid oral preparations **except** when included in Schedule 2; or
(b)in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,

except in preparations for the treatment of children under 2 years of age. TRIPROLIDINE in oral preparations **except**:
(a)when included in Schedule 2; or
(b)for the treatment of children under 2 years of age.

SCHEDULE 4

(Substances marked † are listed in Appendix C) (Substances marked # are listed in Appendix D)
ABACAVIR.
ABATACEPT.
ABCIXIMAB.
ACAMPROSATE CALCIUM.
ACARBOSE.
ACEBUTOLOL.
ACEPROMAZINE.
ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.
ACETARSOL.
ACETAZOLAMIDE.
ACETOHEXAMIDE.
ACETYLCARBROMAL.

ACETYLCHOLINE.
ACETYLCYSTEINE **except**:
(a)when included in Schedule 2; or
(b)in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.
ACETYLDIGITOXIN.
ACETYL ISOVALERYLTYLOSIN.
ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.
ACETYLSTROPHANTHIDIN.
ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of *Herpes labialis* in packs containing 10 g or less.

SCHEDULE 4–continued
ACIPIMOX.
ACITRETIN.
ACOKANTHERA OUABAIO.
ACOKANTHERA SCHIMPERI.
ACONITUM spp. **except**:
(a)when included in Schedule 2;
(b)in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or
(c)in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.
ACRIVASTINE.
ADALIMUMAB.
ADAPALENE.
ADEFOVIR.
ADENOSINE for human therapeutic use in preparations for injection.
ADIPHENINE.
ADONIS VERNALIS.
ADRAFINIL.
ADRENALINE **except**:
(a)when included in Schedule 3; or
(b)in preparations containing 0.02 per cent or less of adrenaline.
ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules. AGALSIDASE.
AGLEPRISTONE.
AGOMELATINE.

SCHEDULE 4–continued
ALATROFLOXACIN MESYLATE.
ALBENDAZOLE **except**:
(a)when included in Schedule 5 or 6; or
(b)in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.
ALCLOMETASONE **except** when included in Schedule 3.
ALCURONIUM.
ALDESLEUKIN.
ALDOSTERONE.
ALEFACEPT.
ALEMTUZUMAB.
ALENDRONIC ACID.
ALFACALCIDOL.
ALFUZOSIN.
ALGLUCERASE.
ALGLUCOSIDASE.
ALISKIREN.
ALLERGENS.
ALLOPURINOL.
ALLYLOESTRENOL.
ALOSETRON.
ALPHADOLONE.
ALPHAXALONE.
ALPRAZOLAM.

SCHEDULE 4–continued

ALPRENOLOL.
ALPROSTADIL.
ALSEROXYLON.
ALTEPLASE.
ALTRENOGEST.
ALTRETAMINE (hexamethylmelamine).
AMANTADINE.
AMBENONIUM CHLORIDE.
AMBUCETAMIDE.
AMBUTONIUM BROMIDE.
AMCINONIDE.
AMETHOCAINE **except**:
(a)when included in Schedule 2; or
(b)in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
AMIFOSTINE.
AMIKACIN.
AMILORIDE.
AMINOCAPROIC ACID.
AMINOGLUTETHIMIDE.
AMINOMETRADINE.
† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals. AMINOPHYLLINE **except** when included in Schedule 3.
AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

SCHEDULE 4–continued
AMINOREX.
AMINOSALICYLIC ACID.
AMIODARONE.
AMIPHENAZOLE.
AMISOMETRADINE.
AMISULPRIDE.
AMITRIPTYLINE.
AMLODIPINE.
AMMI VISNAGA.
AMMONIUM BROMIDE for therapeutic use.
AMODIAQUINE.
AMOROLFINE **except**:
(a)when included in Schedule 2 or 3; or
(b)in preparations for the treatment of tinea pedis. AMOXAPINE.
AMOXYCILLIN.
AMPHOMYCIN.
AMPHOTERICIN.
AMPICILLIN.
AMPRENAVIR.
AMRINONE.
AMSACRINE. AMYL NITRITE.

SCHEDULE 4–continued
AMYLOBARBITONE when packed and labelled for injection.
AMYLOCAINE.
#ANABOLIC STEROIDAL AGENTS. ANAGRELIDE.
ANAKINRA.
ANASTROZOLE.
ANCESTIM.
ANCROD and its immunoglobulin antidote. ANECORTAVE.
#ANDROGENIC STEROIDAL AGENTS.
#ANDROISOXAZOLE.
#ANDROSTANOLONE.
#ANDROSTENEDIOL.
#ANDROSTENEDIONE. ANGIOTENSIN AMIDE. ANIDULAFUNGIN.
ANISTREPLASE.
ANTAZOLINE **except** when included in Schedule 2. ANTIBIOTIC SUBSTANCES **except**:
(a)when separately specified in these Schedules; or
(b)nisin.
ANTIGENS for human therapeutic use **except** when separately specified in this Schedule. ANTIHISTAMINES **except**:
(a)when included in Schedule 2 or 3; or

SCHEDULE 4–continued

(b)when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIPRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules. ARTEMETHER.

ARTICAINE.

ASPIRIN:

(a)when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or

(b)for injection.

ASTEMIZOLE.

ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 4–continued

ATOVAQUONE.

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

(a)in animal feed premixes containing 15 per cent or less of avilamycin activity; or

(b)in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AVOPARCIN.

AZACITIDINE.
AZACYCLONOL.
AZAPERONE.
AZAPROPAZONE.
AZARIBINE.
AZATADINE **except** when included in Schedule 3. AZATHIOPRINE.
AZELAIC ACID **except**:
(a)when included in Schedule 2; or
(b)in preparations containing 1 per cent or less of azelaic acid for non-human use.

SCHEDULE 4–continued
AZELASTINE **except** when included in Schedule 2 or 3.
AZITHROMYCIN.
AZLOCILLIN.
AZTREONAM.
BACAMPICILLIN.
BACITRACIN.
BACLOFEN.
BALSALAZIDE.
BAMBERMYCIN (flavophospholipol) **except**:
(a)when included in Schedule 6; or
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
BAMBUTEROL.
BAMETHAN.
BAMIPINE.
BARBITURATES **except** when separately specified in these Schedules.
BASILIXIMAB.
BECAPLERMIN.
BECLAMIDE.
BECLOMETHASONE **except** when included in Schedule 2.
BEMEGRIDE.
BENACTYZINE.
BENAZEPRIL.

SCHEDULE 4–continued
BENDROFLUAZIDE.
BENETHAMINE PENICILLIN.
BENORYLATE.
BENOXAPROFEN.
BENPERIDOL.
BENSERAZIDE.
BENZATHINE PENICILLIN.
BENZHEXOL.
BENZILONIUM.

BENZOCAINE **except**:
(a)when included in Schedule 2;
(b)in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(c)in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.
BENZOYL PEROXIDE in preparations for human therapeutic use **except**:
(a)when included in Schedule 2; or
(b)in preparations for external use containing 5 per cent or less of benzoyl peroxide. BENZPHETAMINE.
BENZTHIAZIDE. BENZTROPINE (benzatropine).
BENZYDAMINE **except**:
(a)when included in Schedule 2; or
(b)in preparations for dermal use.

SCHEDULE 4–continued

BENZYLPENICILLIN.
BEPRIDIL.
BERACTANT.
BETAHISTINE.
BETAMETHASONE.
BETAXOLOL.
BETHANECHOL CHLORIDE.
BETHANIDINE.
BEVACIZUMAB.
BEVANTOLOL.
BEXAROTENE.
BEZAFIBRATE.
BICALUTAMIDE.
BIFONAZOLE **except**:
(a)when included in Schedule 2;
(b)in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or
(c)in preparations for dermal use for the treatment of tinea pedis. BIMATOPROST.
BIPERIDEN.
BISMUTH COMPOUNDS for cosmetic use, **except**:
(a)bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per cent or less; or
(b)bismuth oxychloride.
BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

SCHEDULE 4–continued

BISOPROLOL.
BIVALIRUDIN.
BLEOMYCIN.
#BOLANDIOL.
#BOLASTERONE.
#BOLAZINE.
#BOLDENONE (dehydrotestosterone).
#BOLENOL.
#BOLMANTALATE.
BORON, including boric acid and borax, for human therapeutic use **except**:
(a)in preparations for internal use containing 6 mg or less of boron per recommended daily dose;
(b)in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or
(c)when present as an excipient.
BORTEZOMIB.
BOSENTAN.
BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.
BRETYLIUM TOSYLATE.
BRIMONIDINE.
BRINZOLAMIDE.
BROMAZEPAM.
BROMIDES, inorganic, for therapeutic use **except** when separately specified in these Schedules.
BROMOCRIPTINE.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 4–continued

BROMOFORM for therapeutic use.
BROMPHENIRAMINE **except** when included in Schedule 2 or 3.
BROMVALETONE.
BRUGMANSIA spp.
BUCLIZINE **except** when included in Schedule 3.
BUDESONIDE **except** when included in Schedule 2.
BUFEXAMAC **except**:
(a)in preparations for dermal use containing 5 per cent or less of bufexamac; or
(b)in suppositories.
BUMETANIDE.
BUPHENINE.
BUPIVACAINE.
BUPROPION.
BUSERELIN.
BUSPIRONE.
BUSULPHAN.

BUTACAINE.
BUTOCONAZOLE **except** when included in Schedule 3.
BUTRACONAZOLE.
BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.
BUTYLCHLORAL HYDRATE.
BUTYL NITRITE.
CABERGOLINE.

SCHEDULE 4–continued

CADMIUM COMPOUNDS for human therapeutic use. CALCIPOTRIOL. ?
CALCITONIN.
CALCITRIOL.
CALCIUM CARBIMIDE for therapeutic use.
CALCIUM POLYSTYRENE SULPHONATE.
CALOTROPIS GIGANTEA.
CALOTROPIS PROCERA.
CALUSTERONE.
CAMPHORATED OIL for therapeutic use.
CAMPHOTAMIDE.
CANDESARTAN CILEXETIL.
CANDICIDIN.
CANINE TICK ANTI-SERUM.
CANTHARIDIN.
CAPECITABINE.
CAPREOMYCIN.
CAPTODIAME.
CAPTOPRIL.
CAPURIDE.
CARAMIPHEN.
CARBACHOL.
CARBAMAZEPINE.
CARBARYL for human therapeutic use.

SCHEDULE 4–continued

CARBAZOCHROME.
CARBENICILLIN.
CARBENOXOLONE for internal use.
CARBETOCIN.
CARBIDOPA.
CARBIMAZOLE.
CARBOCROMEN.
CARBOPLATIN.
CARBOPROST.
CARBROMAL.
CARBUTAMIDE.

CARBUTEROL.
CARINDACILLIN.
CARISOPRODOL.
CARMUSTINE.
CARNIDAZOLE.
CARPROFEN.
CARVEDILOL.
CASPOFUNGIN.
CATHINE.
CEFACETRILE.
CEFACLOR.
CEFADROXIL.
CEFALORIDINE.

SCHEDULE 4–continued

CEFAMANDOLE.
CEFAPIRIN.
CEFAZOLIN.
CEFEPIME.
CEFETAMET.
CEFIXIME.
CEFODIZIME.
CEFONICID.
CEFOPERAZONE.
CEFOTAXIME.
CEFOTETAN.
CEFOTIAM.
CEFOVECIN for veterinary use.
CEFOXITIN.
CEFPIROME.
CEFPODOXIME.
CEFSULODIN.
CEFTAZIDIME.
CEFTIBUTEN.
CEFTIOFUR.
CEFTRIAXONE.
CEFUROXIME.
CELECOXIB.
CELIPROLOL.

SCHEDULE 4–continued

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.
CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.
CEPHALEXIN.

CEPHALONIUM.
CEPHALOTHIN.
CEPHRADINE.
CERIVASTATIN.
CERULETIDE.
CETIRIZINE **except** when included in Schedule 2.
CETRORELIX.
CETUXIMAB.
CHENODEOXYCHOLIC ACID.
CHLORAL FORMAMIDE.
CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.
CHLORALOSE **except** when included in Schedule 6.
CHLORAMBUCIL.
CHLORAMPHENICOL.
CHLORANDROSTENOLONE.
CHLORAZANIL.
CHLORCYCLIZINE.
CHLORDIAZEPOXIDE.
CHLORMERODRIN.

SCHEDULE 4–continued

CHLORMETHIAZOLE.
CHLORMEZANONE.
CHLOROFORM for use in anaesthesia.
4-CHLOROMETHANDIENONE. 2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE. CHLOROQUINE.
CHLOROTHIAZIDE.
CHLOROTRIANISENE.
CHLOROXYDIENONE.
CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.
CHLORPHENTERMINE.
CHLORPROMAZINE.
CHLORPROPAMIDE.
CHLORPROTHIXENE.
CHLORQUINALDOL for human topical use.
CHLORTETRACYCLINE **except** when included in Schedule 5.
CHLORTHALIDONE.
CHLORZOXAZONE.
CHOLERA VACCINE.
CHOLESTYRAMINE (colestyramine) for human therapeutic use.
CHYMOPAPAIN for human therapeutic use.
CICLACILLIN.
CICLESONIDE.
CICLOPIROX **except** when included in Schedule 2 or 3.

SCHEDULE 4–continued

CIDOFOVIR.
CILASTATIN.
CILAZAPRIL.
CIMETIDINE **except** when included in Schedule 3.
CINACALCET.
CINCHOCAINE **except** when included in Schedule 2.
CINOXACIN.
CIPROFLOXACIN.
CISAPRIDE.
CISATRACURIUM BESYLATE.
CISPLATIN.
CITALOPRAM.
CLADRIBINE.
CLANOBUTIN.
CLARITHROMYCIN.
CLAVULANIC ACID.
CLEMASTINE **except** when included in Schedule 3.
CLEMIZOLE.
CLENBUTEROL.
CLIDINIUM BROMIDE.
CLINDAMYCIN.
† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.
CLOBAZAM.

SCHEDULE 4–continued

CLOBETASOL.
CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.
CLOCORTOLONE.
CLODRONIC ACID (includes sodium clodronate).
CLOFAZIMINE.
CLOFENAMIDE.
CLOFIBRATE.
#CLOMIPHENE.
CLOMIPRAMINE.
CLOMOCYCLINE.
CLONAZEPAM.
CLONIDINE.
CLOPAMIDE.
CLOPIDOGREL.
CLOPROSTENOL.
CLORAZEPATE.
CLOREXOLONE.
CLORPRENALINE.

#CLOSTEBOL (4-chlorotestosterone). CLOTRIMAZOLE **except**:
(a)when included in Schedule 2, 3 or 6; or
(b)in preparations for dermal use for the treatment of tinea pedis. CLOXACILLIN.
#CLOZAPINE.

SCHEDULE 4–continued

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.
CODEINE when compounded with one or more other therapeutically active substances:
(a)in divided preparations containing 30 mg or less of codeine per dosage unit; or
(b)in undivided preparations containing 1 per cent or less of codeine,
except when included in Schedule 2 or 3.
CO-DERGOCRINE.
COLASPASE.
COLCHICINE.
COLCHICUM AUTUMNALE.
COLESTIPOL.
COLFOSCERIL PALMITATE for human therapeutic use.
COLISTIN.
COLLAGEN in preparations for injection or implantation:
(a)for tissue augmentation; or
(b)for cosmetic use. CONVALLARIA KEISKI. CONVALLARIA MAJALIS.
COPPER COMPOUNDS for human use **except**:
(a)when separately specified in these Schedules;
(b)in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or
(c)in other preparations containing 5 per cent or less of copper compounds. CORONILLA spp.

SCHEDULE 4–continued

CORTICOSTERONE.
CORTICOTROPHIN.
CORTISONE.
CO-TRIMOXAZOLE.
COUMARIN for therapeutic use (excluding when present as an excipient).
CRYSTAL VIOLET for human use **except** when used as a dermal marker.
CUPRIMYXIN.
CURARE.
CYCLANDELATE.
CYCLIZINE **except** when included in Schedule 3.
CYCLOBENZAPRINE.
CYCLOFENIL. CYCLOHEXIMIDE. CYCLOPENTHIAZIDE.

CYCLOPENTOLATE. CYCLOPHOSPHAMIDE. CYCLOPROPANE for therapeutic use. CYCLOSERINE.
CYCLOSPORIN.
CYCLOTHIAZIDE.
CYCRIMINE.
CYMARIN.
CYPROHEPTADINE **except** when included in Schedule 3. CYPROTERONE.

SCHEDULE 4–continued

CYSTEAMINE for human therapeutic use.
CYTARABINE.
DABIGATRAN.
DACARBAZINE.
DACLIZUMAB.
DACTINOMYCIN.
DALFOPRISTIN.
DALTEPARIN (includes dalteparin sodium).
DANAPAROID (includes danaparoid sodium).
#DANAZOL. DANTHRON for human use. DANTROLENE. DAPSONE.
DAPTOMYCIN.
#DARBEPOETIN.
DARIFENACIN.
DARUNAVIR. DATURA spp. **except**:
(a)when included in Schedule 2; or
(b)when separately specified in this Schedule.
DASATINIB.
DATURA STRAMONIUM (stramonium) **except**:
(a)when included in Schedule 2; or
(b)for smoking or burning.

SCHEDULE 4–continued

DATURA TATULA (stramonium) **except**:
(a)when included in Schedule 2; or
(b)for smoking or burning. DAUNORUBICIN.
DEANOL.
DEBRISOQUINE.
DECAMETHONIUM.
DEFERASIROX.
DEFERIPRONE.
DEFLAZACORT.
#DEHYDROCHLOROMETHYLTESTOSTERONE.
DEHYDROCORTICOSTERONE. DELAVIRDINE (includes delavirdine mesylate).
DEMBREXINE **except** when included in Schedule 5. DEMECARIUM.
DEMECLOCYCLINE.
DEOXYCORTONE. DEOXYRIBONUCLEASE **except**:

(a)when separately specified in this Schedule; or
(b)for external use.
DERACOXIB.
DESFERRIOXAMINE.
DESFLURANE.
DESIPRAMINE.

SCHEDULE 4–continued
DESIRUDIN.
DESLANOSIDE.
DESLORATADINE **except** when included in Schedule 2.
DESLORELIN.
DESMOPRESSIN (D.D.A.V.P.).
DESOGESTREL.
DESONIDE.
DESOXYMETHASONE.
DESVENLAFAXINE.
DETOMIDINE.
DEXAMETHASONE.
DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.
DEXFENFLURAMINE.
DEXMEDETOMIDINE.
DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.
#DEXTROPROPOXYPHENE:
(a)in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or
(b)liquid preparations containing 2.5 per cent or less of dextropropoxyphene. DEXTRORPHAN (excluding its stereoisomers).
DIAMTHAZOLE.
DIAVERIDINE.
DIAZEPAM.
DIAZOXIDE.

SCHEDULE 4–continued
DIBENZEPIN.
DIBOTERMIN.
DIBROMOPROPAMIDINE for therapeutic use **except** when included in Schedule 2.
DICHLORALPHENAZONE.
DICHLOROPHEN for human therapeutic use.
DICHLORPHENAMIDE.
DICLOFENAC **except**:
(a) when included in Schedule 2 or 3; or
(b) in preparations for dermal use. DICLOXACILLIN.

DICYCLOMINE.
DIDANOSINE.
DIENESTROL.
DIENOGEST.
DIETHAZINE.
DIETHYLCARBAMAZINE for human therapeutic use.
DIETHYLPROPION.
DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.
DIFLORASONE.
DIFLOXACIN.
DIFLUCORTOLONE.
DIFLUNISAL.
DIGITALIS LANATA.

SCHEDULE 4–continued

DIGITALIS PURPUREA.
DIGITOXIN.
DIGOXIN.
DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).
DIHYDRALAZINE.
DIHYDROCODEINE when compounded with one or more other therapeutically active substances:
(a)in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine, except when included in Schedule 2 or 3.
DIHYDROERGOTOXINE.
#DIHYDROLONE.
DIHYDROSTREPTOMYCIN.
DIHYDROTACHYSTEROL.
† DI-IODOHYDROXYQUINOLINE (iodoquinol) **except**:
(a)when included in Schedule 3; or
(b)for human internal use. DIISOPROPYLAMINE DICHLOROACETATE. DILTIAZEM.
DIMENHYDRINATE **except** when included in Schedule 2 or 3.
DIMERCAPROL.
#DIMETHANDROSTANOLONE.
#DIMETHAZINE.

SCHEDULE 4–continued

DIMETHINDENE **except** when included in Schedule 3.
DIMETHOTHIAZINE.
DIMETHOXANATE.
DIMETHYL SULFOXIDE for therapeutic use **except**:

(a)when included in Schedule 6; or

(b)in in-vitro test kits. DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

#DINOPROST.

#DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use. DIPHENHYDRAMINE **except** when included in Schedule 2 or 3. DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

SCHEDULE 4–continued

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6. DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

SCHEDULE 4–continued

DOXAZOSIN.
DOXEPIN.
DOXORUBICIN.
DOXYCYCLINE.
DOXYLAMINE **except** when included in Schedule 2 or 3.
DROPERIDOL.
DROSPIRENONE.
DROSTANOLONE. DROTRECOGIN.
DUBOISIA LEICHHARDTII **except** when included in Schedule 2.
DUBOISIA MYOPOROIDES **except** when included in Schedule 2.
DULOXETINE.
DUTASTERIDE.
DYDROGESTERONE.
ECONAZOLE **except**:
(a)when included in Schedule 2, 3 or 6; or
(b)in preparations for dermal use for the treatment of tinea pedis.
ECOTHIOPATE (includes ecothiopate iodide).
ECTYLUREA.
EDETIC ACID for human therapeutic use **except**:
(a)in preparations containing 0.25 per cent or less of edetic acid;
(b)as dicobalt edetate in preparations for the treatment of cyanide poisoning; or
(c)in contact lens preparations.
EDOXUDINE.

SCHEDULE 4–continued

EDROPHONIUM.
EFALIZUMAB.
EFAVIRENZ.
EFLORNITHINE.
ELETRIPTAN.
ELTENAC.
EMEPRONIUM.
EMETINE **except** in preparations containing 0.2 per cent or less of emetine.
EMTRICITABINE.
ENALAPRIL.
ENESTEBOL.
ENFLURANE for therapeutic use.
ENFUVIRTIDE.
ENOXACIN.
ENOXAPARIN.
ENOXIMONE.
ENPROSTIL.
ENROFLOXACIN.
ENTACAPONE.
ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.
EPHEDRINE. EPICILLIN. EPINASTINE.

SCHEDULE 4–continued
EPIRUBICIN.
#EPITIOSTANOL.
EPLERENONE.
#EPOETINS.
EPOPROSTENOL.
EPROSARTAN.
EPTIFIBATIDE.
ERGOMETRINE.
ERGOT.
ERGOTAMINE.
ERGOTOXINE.
ERLOTINIB.
ERTAPENEM. ERYSIMUM spp. ERYTHROMYCIN.
#ERYTHROPOIETIN.
#ERYTHROPOIETINS **except** when separately specified in these Schedules.
ESCITALOPRAM.
ESMOLOL.
ESOMEPRAZOLE.
ESTRAMUSTINE.
ESTROPIPATE (piperazine oestrone sulfate).
ETANERCEPT.
ETHACRYNIC ACID.

SCHEDULE 4–continued
ETHAMBUTOL.
ETHAMIVAN.
ETHANOLAMINE in preparations for injection.
ETHCHLORVYNOL.
ETHER for use in anaesthesia.
ETHINAMATE.
ETHINYLOESTRADIOL.
ETHIONAMIDE.
ETHISTERONE.
ETHOGLUCID.
ETHOHEPTAZINE.
ETHOPROPAZINE.
ETHOSUXIMIDE.
ETHOTOIN.
ETHOXZOLAMIDE.
ETHYL CHLORIDE for human therapeutic use.
ETHYLDIENOLONE.

† ETHYLHEXANEDIOL for animal use.
ETHYLMORPHINE when compounded with one or more other therapeutically active substances:
(a)in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or
(b)in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine,
except when included in Schedule 2.

SCHEDULE 4–continued
ETHYLOESTRENOL.
ETHYNODIOL.
ETIDOCAINE.
ETIDRONIC ACID (includes disodium etidronate):
(a)for internal use; or
(b)in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.
ETILEFRIN.
ETIPROSTON.
ETODOLAC.
ETOFENAMATE **except** when included in Schedule 2.
ETONOGESTREL.
ETOPOSIDE.
ETORICOXIB.
ETRETINATE.
EVEROLIMUS.
EXEMESTANE.
EXENATIDE.
EZETIMIBE.
FAMCICLOVIR.
FAMOTIDINE **except** when included in Schedule 2.
FELBINAC **except** when included in Schedule 2.
FELODIPINE.
FELYPRESSIN.

SCHEDULE 4–continued
FENBUFEN.
FENCAMFAMIN.
FENCLOFENAC.
FENFLURAMINE.
FENOFIBRATE.
FENOLDOPAM.
FENOPROFEN.
FENOTEROL.
FENPIPRAMIDE.

FENPIPRANE.
FENPROPOREX.
FENPROSTALENE.
FEXOFENADINE **except** when included in Schedule 2. FIBRINOLYSIN **except** for external use. FILGRASTIM.
FINASTERIDE.
FIROCOXIB.
FLECAINIDE.
FLEROXACIN.
FLOCTAFENINE.
FLORFENICOL.
FLUANISONE.
FLUCLOROLONE.
FLUCLOXACILLIN.

SCHEDULE 4–continued

FLUCONAZOLE except when included in Schedule 3.
FLUCYTOSINE.
FLUDARABINE.
FLUDROCORTISONE.
FLUFENAMIC ACID.
FLUMAZENIL.
FLUMETHASONE.
FLUMETHIAZIDE.
FLUNISOLIDE.
FLUNIXIN MEGLUMINE.
FLUOCINOLONE.
FLUOCINONIDE.
FLUOCORTIN.
FLUOCORTOLONE.
FLUORESCEIN in preparations for injection.
FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.
FLUOROMETHOLONE.
FLUOROURACIL.
FLUOXETINE.
 # FLUOXYMESTERONE. FLUPENTHIXOL. FLUPHENAZINE. FLUPROSTENOL. FLURANDRENOLONE.

SCHEDULE 4–continued

FLURAZEPAM.
FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.
FLUSPIRILENE.
FLUTAMIDE.
FLUTICASONE **except** when included in Schedule 2.
FLUVASTATIN.
FLUVOXAMINE.
FOLIC ACID in preparations for human use for injection.
FOLINIC ACID in preparations for human use for injection.
FOLLICLE-STIMULATING HORMONE **except** when separately specified in this Schedule.
#FOLLITROPIN ALPHA.
#FOLLITROPIN BETA. FOMIVIRSEN. FONDAPARINUX.
#FORMEBOLONE.
FORMESTANE.
FORMOTEROL.
FOSAMPRENAVIR.
FOSAPREPITANT.
FOSCARNET.
FOSFESTROL (diethylstilboestrol diphosphate). FOSINOPRIL.

SCHEDULE 4–continued
FOSPHENYTOIN.
FOTEMUSTINE.
FRAMYCETIN.
FULVESTRANT.
FURALTADONE.
FURAZABOL. FURAZOLIDONE. FUROSEMIDE (frusemide). FUSIDIC ACID. GABAPENTIN. GALANTAMINE. GALANTHUS spp. GALLAMINE. GALSULFASE. GANCICLOVIR. GANIRELIX. GATIFLOXACIN. GEFITINIB. GEMCITABINE. GEMEPROST. GEMFIBROZIL. GEMIFLOXACIN. GENTAMICIN. GESTODENE.

SCHEDULE 4–continued
GESTONORONE.
GESTRINONE.
GHRH INJECTABLE PLASMID.
GITALIN.
GLATIRAMER ACETATE.
GLIBENCLAMIDE.
GLIBORNURIDE.
GLICLAZIDE.
GLIMEPIRIDE.
GLIPIZIDE.
GLISOXEPIDE.
GLUTATHIONE for parenteral use.
GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.
GLYCOPYRRONIUM in preparations for injection. GLYMIDINE.
GnRH VACCINE.
GONADORELIN.
GONADOTROPHIC HORMONES **except** when separately specified in this Schedule. GOSERELIN.
GRAMICIDIN.
GRANISETRON.
GREPAFLOXACIN.

SCHEDULE 4–continued

GRISEOFULVIN.
GUAIPHENESIN for human therapeutic use **except**:
(a)in oral liquid preparations containing 2 per cent or less of guaiphenesin; or
(b)in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.
GUANABENZ.
GUANACLINE.
GUANETHIDINE.
GUANIDINE.
HACHIMYCIN.
HAEMATIN.
HAEMOPHILUS INFLUENZAE VACCINE.
HALCINONIDE.
HALOFANTRINE.
HALOFENATE.
HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.
HALOPERIDOL.
HALOTHANE for therapeutic use.
HEMEROCALLIS (Hemerocallis flava).
HEPARINS for internal use **except** when separately specified in this Schedule.
HEPATITIS A VACCINE.
HEPATITIS B VACCINE.
HETACILLIN.

SCHEDULE 4–continued

HEXACHLOROPHANE:
(a)in preparations for use on infants; or
(b)in other preparations **except**:
(i)when included in Schedule 2 or 6; or
(ii)in preparations containing 0.75 per cent or less of hexachlorophane.
HEXAMETHONIUM.
HEXETIDINE for human internal use.
HEXOBENDINE.
HEXOCYCLIUM.

HEXOPRENALINE.
HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.
HOMATROPINE.
HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.
HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:
(a)for tissue augmentation;
(b)for cosmetic use; or
(c)for the treatment of animals.
HYDRALAZINE.
HYDRARGAPHEN.
HYDROCHLOROTHIAZIDE.
HYDROCORTISONE:
(a)for human use **except** when included in Schedule 2 or 3; or
(b)for the treatment of animals.

SCHEDULE 4–continued

HYDROCYANIC ACID for therapeutic use.
HYDROFLUMETHIAZIDE.
HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:
(a)when included in Schedule 2; or
(b)in hair preparations containing 1 per cent or less of hydroquinone.
HYDROXYCHLOROQUINE.
HYDROXYEPHEDRINE.
HYDROXYPHENAMATE.
HYDROXYPROGESTERONE.
HYDROXYSTENOZOL.
HYDROXYUREA.
HYDROXYZINE.
HYGROMYCIN.
HYOSCINE **except** when included in Schedule 2.
HYOSCYAMINE **except** when included in Schedule 2.
HYOSCYAMUS NIGER **except**:
(a)when included in Schedule 2; or
(b)in a pack containing 0.03 mg or less of total solanaceous alkaloids.
HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.
HYPROMELLOSE in preparations for injection.
IBAFLOXACIN for veterinary use.
IBANDRONIC ACID.
IBRITUMOMAB.

SCHEDULE 4–continued

IBUFENAC.
IBUPROFEN **except**:

(a)when included in or expressly excluded from Schedule 2 or 3; or
(b)in preparations for dermal use.
IBUTEROL.
IBUTILIDE.
IDARUBICIN.
IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.
IDURSULFASE.
IFOSFAMIDE.
ILOPROST.
IMATINIB.
IMIDAPRIL.
IMIGLUCERASE.
IMIPENEM.
IMIPRAMINE.
IMIQUIMOD.
IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.
INDAPAMIDE.
INDINAVIR.
INDOMETHACIN **except** when included in Schedule 2.
INDOPROFEN.
INDORAMIN**.**

SCHEDULE 4–continued
INFLIXIMAB.
INFLUENZA AND CORYZA VACCINES:
(a)for parenteral use; or
(b)for nasal administration.
#INSULIN-LIKE GROWTH FACTOR I.
#INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule. INSULINS.
INTERFERONS.
INTERLEUKINS **except** when separately specified in these Schedules. IODOTHIOURACIL.
IPRATROPIUM **except** when included in Schedule 2. IPRIFLAVONE.
IPRINDOLE.
IPRONIAZID.
IRBESARTAN.
IRINOTECAN.
IRON COMPOUNDS in injectable preparations for human use. ISOAMINILE.
ISOAMYL NITRITE. ISOBUTYL NITRITE. ISOCARBOXAZID.
ISOCONAZOLE **except** when included in Schedule 2, 3 or 6. ISOETARINE.

SCHEDULE 4–continued
ISOFLURANE for therapeutic use.

ISOMETHEPTENE.
ISONIAZID.
ISOPRENALINE.
ISOPRINOSINE.
ISOPROPAMIDE **except** when included in Schedule 2. ISOSORBIDE DINITRATE **except** when included in Schedule 3. ISOSORBIDE MONONITRATE.
ISOTRETINOIN. ISOXICAM. ISOXSUPRINE. ISRADIPINE. ITRACONAZOLE. IVABRADINE. IVERMECTIN:
(a)for human use; or
(b)for the treatment of mange in dogs. IXABEPILONE.
KANAMYCIN.
KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.
KETAZOLAM.

SCHEDULE 4–continued
KETOCONAZOLE **except**:
(a)when included in Schedule 2;
(b)in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or
(c)in preparations for dermal use for the treatment of tinea pedis.
KETOPROFEN **except**:
(a)in preparations for dermal use; or
(b)when included in Schedule 3. KETOROLAC (includes ketoralac trometamol). KETOTIFEN **except** when included in Schedule 2. KHELLIN.
KITASAMYCIN **except**:
(a)when included in Schedule 5 ; or
(b)in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL.
LACIDIPINE.
LAMIVUDINE.
LAMOTRIGINE.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE.
LANTHANUM for therapeutic use.
LAPATINIB.

SCHEDULE 4–continued
LARONIDASE.
LAROPIPRANT.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:
(a)when present as an excipient; or
(b) when separately specified in these Schedules.
† LEAD for human therapeutic use. LEFETAMINE.
LEFLUNOMIDE.
LENALIDOMIDE.
LENOGRASTIM.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVAMISOLE:
(a)for human therapeutic use; or
(b)in preparations for the prevention or treatment of heartworm in dogs.
LEVETIRACETAM.
LEVOBUNOLOL.

SCHEDULE 4–continued
LEVOBUPIVACAINE.
LEVOCABASTINE **except** when included in Schedule 2.
LEVODOPA.
LEVOMEPROMAZINE.
LEVONORGESTREL **except** when included in Schedule 3.
LEVOSIMENDAN.
LIDOFLAZINE.
LIGNOCAINE **except**:
(a)when included in Schedule 2;
(b)in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or
(c)in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.
LINCOMYCIN.
LINDANE for human therapeutic use **except** when included in Schedule 2.
LINEZOLID.
LIOTHYRONINE.
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use **except**:
(a)when included in Schedule 2;
(b)when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or
(c)in preparations containing 0.01 per cent or less of lithium.
LODOXAMIDE **except** when included in Schedule 2.

SCHEDULE 4–continued

LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE **except** when included in Schedule 2. LOPINAVIR.
LOPRAZOLAM.
LORACARBEF.
LORATADINE **except** when included in Schedule 2. LORAZEPAM.
LORMETAZEPAM.
LOSARTAN.
LOXAPINE.
LUMEFANTRINE.
LUMIRACOXIB.
LUTEINISING HORMONE **except** in ovulation test kits. LYMECYCLINE.
MAFENIDE **except** when included in Schedule 6.
MANDRAGORA OFFICINARUM.
MANNOMUSTINE.
MAPROTILINE.
MARAVIROC.
MARBOFLOXACIN.
MAROPITANT.

SCHEDULE 4–continued

MAZINDOL.
MEASLES VACCINE.
MEBANAZINE.
MEBEVERINE.
MEBHYDROLIN.
MEBOLAZINE.
MEBUTAMATE.
MECAMYLAMINE.
MECASERMIN.
MECILLINAM.
MECLOCYCLINE.
MECLOFENAMATE.
MECLOFENOXATE.
MECLOZINE **except** when included in Schedule 2.
MEDAZEPAM.
MEDETOMIDINE.
MEDIGOXIN (methyldigoxin).
MEDROXYPROGESTERONE.
MEDRYSONE.
MEFENAMIC ACID **except** when included in Schedule 2.
MEFENOREX.
MEFLOQUINE.

MEFRUSIDE.
MEGESTROL.

SCHEDULE 4–continued
MELAGATRAN.
MELATONIN for human use.
MELENGESTROL **except** when included in Schedule 6. MELOXICAM.
MELPHALAN.
MEMANTINE.
MENINGOCOCCAL VACCINE.
MENOTROPHIN.
MEPACRINE.
MEPENZOLATE.
MEPHENESIN.
MEPHENTERMINE.
MEPINDOLOL.
MEPITIOSTANE. MEPIVACAINE. MEPROBAMATE. MEPTAZINOL.
MEPYRAMINE **except** when included in Schedule 2 or 3. MEQUITAZINE.
MERCAPTOMERIN.
MERCAPTOPURINE.
MERCURY for cosmetic or therapeutic use **except**:
(a)when separately specified in these Schedules; or
(b)in a sealed device which prevents access to the mercury.

SCHEDULE 4–continued
MEROPENEM.
MERSALYL.
#MESABOLONE.
MESALAZINE.
MESNA.
#MESTANOLONE (androstalone).
#MESTEROLONE.
MESTRANOL.
#METANDIENONE.
METARAMINOL.
#METENOLONE.
METERGOLINE.
METFORMIN.
METHACHOLINE.
METHACYCLINE.
METHALLENOESTRIL.
#METHANDRIOL.
METHANTHELINIUM.
METHAZOLAMIDE.
METHDILAZINE **except** when included in Schedule 3.
#METHENOLONE.

METHICILLIN.
METHIMAZOLE.
METHISAZONE.

SCHEDULE 4–continued
METHIXENE.
METHOCARBAMOL.
METHOHEXITONE.
METHOIN.
METHOTREXATE.
METHOXAMINE **except**:
(a) when included in Schedule 2; or
(b) in preparations for external use containing 1 per cent or less of methoxamine. METHOXSALEN.
METHOXYFLURANE.
METHSUXIMIDE.
METHYCLOTHIAZIDE. METHYL AMINOLEVULINATE. #METHYLANDROSTANOLONE.
#METHYLCLOSTEBOL.
METHYLDOPA.
METHYLENE BLUE in preparations for injection. METHYLERGOMETRINE.
METHYL MERCURY for therapeutic use. METHYLPENTYNOL. METHYLPHENOBARBITONE. METHYLPREDNISOLONE.
METHYL SALICYLATE in preparations for internal therapeutic use.
#METHYLTESTOSTERONE.

SCHEDULE 4–continued
METHYLTHIOURACIL.
#METHYLTRIENOLONE.
METHYPRYLONE.
METHYSERGIDE.
METOCLOPRAMIDE **except** when included in Schedule 3. METOLAZONE.
METOPROLOL.
#METRIBOLONE.
METRIFONATE (trichlorfon) for human therapeutic use.
METRONIDAZOLE.
METYRAPONE.
MEXILETINE.
MEZLOCILLIN.
MIANSERIN.
MIBEFRADIL.
MIBOLERONE.
MICONAZOLE **except**:
(a)when included in Schedule 2, 3 or 6; or
(b)in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.
MIDODRINE.
MIGLITOL.
MIGLUSTAT.
MILBEMYCIN OXIME **except** when included in Schedule 5.

SCHEDULE 4–continued

MILRINONE.
MINOCYCLINE.
MINOXIDIL **except** when included in Schedule 2.
MIRTAZAPINE.
MISOPROSTOL.
MITOBRONITOL.
MITOMYCIN.
MITOTANE.
MITOXANTRONE.
MITRATAPIDE.
MIVACURIUM CHLORIDE.
MOCLOBEMIDE.
MODAFINIL.
MOLGRAMOSTIM.
MOLINDONE.
MOMETASONE **except** when included in Schedule 2.
MONENSIN **except**:
(a)when included in Schedule 5 or 6; or
(b)in animal feeds containing 360 mg/kg or less of antibiotic substances.
MONOBENZONE and other alkyl ethers of hydroquinone for human therapeutic use or cosmetic use.
MONOCLONAL ANTIBODIES for therapeutic use **except**:
(a)in diagnostic test kits; or
(b)when separately specified in these Schedules.

SCHEDULE 4–continued

MONTELUKAST.
MOPERONE.
MORAZONE.
MORICIZINE.
MOTRAZEPAM.
MOTRETINIDE.
MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.
MOXIFLOXACIN.
MOXONIDINE.
MUMPS VACCINE.
MUPIROCIN.
MURAGLITAZAR.

MUROMONAB.
MUSTINE (nitrogen mustard).
MYCOPHENOLIC ACID (includes mycophenolate mofetil).
NABUMETONE.
NADOLOL.
NADROPARIN.
NAFARELIN.
NAFTIDROFURYL.
NALBUPHINE.
NALIDIXIC ACID.
NALORPHINE.

SCHEDULE 4–continued

NALOXONE.
NALTREXONE.
NANDROLONE.
NAPROXEN **except** when included in Schedule 2.
NARASIN **except**:
(a)when included in Schedule 6; or
(b)in animal feeds containing 100 mg/kg or less of antibiotic substances. NARATRIPTAN.
NATALIZUMAB.
NATAMYCIN.
NATEGLINIDE.
NEBACUMAB.
NEDOCROMIL.
NEFAZODONE.
NEFOPAM.
NELFINAVIR (includes nelfinavir mesylate). NEOMYCIN.
NEOSTIGMINE.
NEPAFENAC. NERIUM OLEANDER. NESIRITIDE. NETILMICIN. NEVIRAPINE. NIALAMIDE.

SCHEDULE 4–continued

NICARDIPINE.
NICERGOLINE.
NICOFURANOSE.
NICORANDIL.
NICOTINE in preparations for human therapeutic use **except**:
(a)when included in Schedule 2; or
(b)for use as an aid in withdrawal from tobacco smoking in chewing gum, lozenges, or preparations for sublingual or transdermal use.
NICOTINIC ACID for human therapeutic use **except**:
(a)when contained in other Schedules;
(b)in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(c)nicotinamide.
NICOUMALONE.
NIFEDIPINE.
NIFENAZONE.
NIKETHAMIDE.
NILOTINIB.
NILUTAMIDE.
NIMESULIDE.
NIMODIPINE.
NIMORAZOLE.
NIRIDAZOLE.
NISOLDIPINE.
NITRAZEPAM.

SCHEDULE 4–continued
NITRENDIPINE.
NITRIC OXIDE for human therapeutic use.
NITROFURANTOIN.
NITROFURAZONE.
NITROUS OXIDE for therapeutic use.
NITROXOLINE.
NIZATIDINE **except** when included in Schedule 2.
NOMIFENSINE.
NORADRENALINE.
#19-NORANDROSTENEDIOL.
#19-NORANDROSTENEDIONE.
#NORANDROSTENOLONE.
#NORBOLETHONE.
#NORCLOSTEBOL.
NORELGESTROMIN.
#NORETHANDROLONE.
NORETHISTERONE.
NORFLOXACIN.
NORGESTREL.
#NORMETHANDRONE.
NORTRIPTYLINE.
NOVOBIOCIN.
NOXIPTYLINE.
NYSTATIN **except** when included in Schedule 2 or 3.

SCHEDULE 4–continued
OCTAMYLAMINE.
OCTATROPINE.
OCTREOTIDE.
OCTYL NITRITE.
OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.
OESTROGENS **except** when separately specified in these Schedules.
OESTRONE.
OFLOXACIN.
OLANZAPINE.
OLEANDOMYCIN **except**:
(a)when included in Schedule 5; or
(b)in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.
OLEANDRIN.
OLMESARTAN.
OLOPATADINE.
OLSALAZINE.
OMALIZUMAB.
OMEPRAZOLE.
ONDANSETRON.
OPIPRAMOL.
ORBIFLOXACIN.
ORCIPRENALINE.

SCHEDULE 4–continued

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use **except**:
(a)when separately specified in these Schedules; or
(b)in preparations containing 2 per cent or less of malathion for external use. ORLISTAT **except** when included in Schedule 3.
ORNIDAZOLE.
ORNIPRESSIN.
ORPHENADRINE.
ORTHOPTERIN.
OSELTAMIVIR.
OUABAIN.
#OVANDROTONE.
#OXABOLONE.
OXACILLIN.
OXALIPLATIN.
OXANDROLONE. OXAPROZIN. OXAZEPAM. OXCARBAZEPINE.
OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.
OXETACAINE (oxethazaine) **except** when included in Schedule 2.
OXICONAZOLE **except**:
(a)when included in Schedule 2 or 3; or
(b)in preparations for the treatment of tinea pedis.

SCHEDULE 4–continued

OXITROPIUM.

OXOLAMINE.
OXOLINIC ACID.
OXPENTIFYLLINE (pentoxifylline).
OXPRENOLOL.
OXYBUPROCAINE.
OXYBUTYNIN.
#OXYMESTERONE.
#OXYMETHOLONE.
OXYPHENBUTAZONE.
OXYPHENCYCLIMINE.
OXYPHENONIUM.
OXYTETRACYCLINE **except** when included in Schedule 5. OXYTOCIN.
PACLITAXEL.
PALIFERMIN.
PALIPERIDONE.
PALIVIZUMAB.
PALONOSETRON.
PAMAQUIN.
PAMIDRONIC ACID (includes disodium pamidronate). PANCREATIC ENZYMES **except**:
(a)in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or
(b)when separately specified in these Schedules.

SCHEDULE 4–continued

PANCURONIUM.
PANITUMUMAB.
PANTOPRAZOLE **except** when included in Schedule 3.
PAPAVERINE in preparations for injection.
PARACETAMOL:
(a)when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;
(b)in slow release tablets or capsules containing more than 665 mg of paracetamol;
(c)in non-slow release tablets or capsules containing more than 500 mg of paracetamol;
(d)in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or
(e)for injection.
PARALDEHYDE.
PARAMETHADIONE.
PARAMETHASONE.
PARECOXIB.
PARICALCITOL.
PAROMOMYCIN.
PAROXETINE.

PECAZINE.
PEFLOXACIN.
PEGAPTANIB.
PEGFILGRASTIM.
PEGINTERFERON.

SCHEDULE 4–continued
PEGVISOMANT.
PEMETREXED.
PEMOLINE.
PEMPIDINE.
PENBUTOLOL.
PENCICLOVIR **except** when included in Schedule 2.
PENETHAMATE.
PENICILLAMINE.
PENTAERYTHRITYL TETRANITRATE.
PENTAGASTRIN.
PENTAMETHONIUM.
PENTAMIDINE (includes pentamidine isethionate).
PENTHIENATE.
PENTOBARBITONE when packed and labelled for injection.
PENTOLINIUM.
PENTOSAN POLYSULFATE SODIUM.
PERGOLIDE.
PERHEXILINE.
PERICYAZINE.
PERINDOPRIL.
PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.
PERPHENAZINE.
PERTUSSIS ANTIGEN.

SCHEDULE 4–continued
PHENACEMIDE.
PHENACETIN for therapeutic use (excluding when present as an excipient).
PHENAGLYCODOL.
PHENAZONE **except** when included in Schedule 2 or 5.
PHENAZOPYRIDINE.
PHENELZINE.
PHENETICILLIN.
PHENFORMIN.
PHENGLUTARIMIDE.
PHENINDIONE.
PHENIRAMINE **except** when included in Schedule 2 or 3. PHENISATIN.
PHENOBARBITONE.
PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.
PHENOXYBENZAMINE.
PHENOXYMETHYLPENICILLIN.
PHENSUXIMIDE.
PHENTERMINE. PHENTHIMENTONIUM. PHENTOLAMINE.
PHENYLBUTAZONE.

SCHEDULE 4–continued

PHENYLEPHRINE:
(a)in preparations for injection; or
(b)in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.
PHENYLPROPANOLAMINE.
PHENYLTOLOXAMINE.
PHENYTOIN.
PHOLCODINE:
(a)in divided preparations containing 100 mg or less of pholcodine per dosage unit; or
(b)in undivided preparations containing 2.5 per cent or less of pholcodine,
except when included in Schedule 2.
PHTHALYLSULFATHIAZOLE.
PHYSOSTIGMINE.
PICROTOXIN.
PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.
PIMECROLIMUS.
PIMOBENDAN.
PIMOZIDE.
PINACIDIL.
PINDOLOL.
PIOGLITAZONE.
PIPECURONIUM.
PIPEMIDIC ACID.

SCHEDULE 4–continued

PIPENZOLATE.
PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Australian Register of Therapeutic Goods in preparations:
(a)for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:
(i)the tablet or capsule form contains 125 mg or less of kavalactones per tablet or capsule; or
(ii)the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;
and, where containing more than 25 mg of kavalactones per dose, compliant

with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or
(c)in dermal preparations.
PIPERACILLIN.
PIPERIDINE.
PIPERIDOLATE.
PIPOBROMAN.
PIPOTHIAZINE.
PIPRADROL.
PIRACETAM.
PIRBUTEROL.
PIRENOXINE (catalin).
PIRENZEPINE.
PIRETANIDE.

PIROXICAM **except** in preparations for dermal use.
PIRPROFEN.
PITUITARY HORMONES **except** when separately specified in these Schedules. PIVAMPICILLIN.
PIZOTIFEN.
PLICAMYCIN.
PNEUMOCOCCAL VACCINE.
PODOPHYLLOTOXIN for human use:
(a)internally;
(b)in preparations for the treatment of anogenital warts; or
(c)in other preparations **except** when included in Schedule 2 or 3.
PODOPHYLLUM EMODI (podophyllin) for human use:
(a)internally;
(b)in preparations for the treatment of anogenital warts; or
(c)in other preparations **except** when included in Schedule 2 or 3.
PODOPHYLLUM PELTATUM (podophyllin) for human use:
(a)internally;
(b)in preparations for the treatment of anogenital warts; or
(c)in other preparations **except** when included in Schedule 2 or 3.
POLIDEXIDE.
POLIOMYELITIS VACCINE.
POLYACRYLAMIDE in preparations for injection or implantation:
(a)for tissue augmentation; or
(b)for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:
(a)for tissue augmentation; or
(b)for cosmetic use.
POLYMYXIN.
POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.
POLYTHIAZIDE.
PORACTANT.
POSACONAZOLE.
POTASSIUM BROMIDE for therapeutic use.
POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:
(a)when containing less than 550 mg of potassium chloride per dosage unit;
(b)in preparations for oral rehydration therapy;
(c)in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or
(d)in preparations for enteral feeding.
POTASSIUM PERCHLORATE for therapeutic use.
PRACTOLOL.
PRALIDOXIME.
PRAMIPEXOLE.
PRAMOCAINE.
PRAMPINE.
PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).
PRAVASTATIN.

SCHEDULE 4–continued
PRAZEPAM.
PRAZIQUANTEL for human therapeutic use.
PRAZOSIN.
PREDNISOLONE.
PREDNISONE.
PREGABALIN.
PREGNENOLONE.
PRENALTEROL.
PRENYLAMINE.
PRILOCAINE **except** when included in Schedule 2.
PRIMAQUINE.
PRIMIDONE.
PROBENECID.
PROBUCOL.
PROCAINAMIDE.
PROCAINE.
PROCAINE PENICILLIN.
PROCARBAZINE.
PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2. PROGESTERONE **except** when included in Schedule 5. PROGESTOGENS **except** when separately specified in these Schedules.
PROGLUMIDE.
PROGUANIL.

SCHEDULE 4–continued

PROLINTANE.
PROMAZINE.
PROMETHAZINE **except** when included in Schedule 2 or 3.
PROMOXOLANE.
PROPAFENONE.
PROPAMIDINE for therapeutic use **except** when included in Schedule 2.
PROPANIDID.
PROPANTHELINE.
PROPENTOFYLLINE.
PROPETANDROL.
PROPIONIBACTERIUM ACNES for therapeutic use.
PROPOFOL.
PROPRANOLOL.
PROPYLHEXEDRINE.
PROPYLTHIOURACIL.
PROPYPHENAZONE.
PROQUAZONE.
PROSCILLARIDIN.
PROSTAGLANDINS **except** when separately specified in this Schedule.
PROSTIANOL.
PROTAMINE.
PROTHIONAMIDE.
PROTHIPENDYL.
PROTIRELIN.

SCHEDULE 4–continued

PROTOVERATRINES.
PROTRIPTYLINE.
PROXYMETACAINE.
PSEUDOEPHEDRINE **except** when included in Schedule 3.
PYRAZINAMIDE.
PYRIDINOLCARBAMATE.
PYRIDOSTIGMINE.
PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:
(a)in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b)in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.
PYRIMETHAMINE.
PYROVALERONE.
PYRVINIUM.
QUAZEPAM.
QUETIAPINE.
QUINAGOLIDE.
QUINAPRIL.
QUINBOLONE.
QUINETHAZONE.
QUINIDINE.
QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

SCHEDULE 4–continued
QUINISOCAINE (dimethisoquin).
QUINUPRISTIN.
RABEPRAZOLE.
RABIES VACCINE.
RACTOPAMINE **except** when included in Schedule 5.
RALOXIFENE.
RALTEGRAVIR.
RALTITREXED.
RAMIPRIL.
RANIBIZUMAB.
RANITIDINE **except**:
(a)when included in Schedule 2; or
(b)in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer's original pack containing not more than 14 dosage units.
RAPACURONIUM.
RASAGILINE.
RASBURICASE.
RAUWOLFIA SERPENTINA.
RAUWOLFIA VOMITORIA.
RAZOXANE.
REBOXETINE.
REMOXIPRIDE.
REPAGLINIDE.
RESERPINE.

SCHEDULE 4–continued
RETEPLASE.
RIBAVIRIN.
RIFABUTIN.

RIFAMPICIN.
RIFAMYCIN.
RIFAPENTINE.
RILUZOLE.
RIMEXOLONE.
RIMITEROL.
RIMONABANT.
RISEDRONIC ACID.
RISPERIDONE.
RITODRINE.
RITONAVIR.
RITUXIMAB.
RIVASTIGMINE.
RIZATRIPTAN.
ROCURONIUM.
ROFECOXIB.
ROLITETRACYCLINE.
ROMIFIDINE.
ROMIPLOSTIM.
RONIDAZOLE.

SCHEDULE 4–continued

ROPINIROLE.
ROPIVACAINE.
ROSIGLITAZONE.
ROSOXACIN.
ROSUVASTATIN.
ROTIGOTINE.
ROXIBOLONE. ROXITHROMYCIN. RUBELLA VACCINE.
RUBOXISTAURIN.
SALBUTAMOL **except** when included in Schedule 3.
SALCATONIN.
SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.
SALINOMYCIN **except**:
(a)when included in Schedule 6; or
(b)in animal feeds containing 60 mg/kg or less of antibiotic substances.
SALMETEROL.
SAQUINAVIR.
SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.
SCOPOLIA CARNIOLICA for therapeutic use.
SELEGILINE.

SCHEDULE 4–continued

SELENIUM:
(a)for human oral use with a recommended daily dose of more than 300 micrograms; or
(b)for the treatment of animals **except**:
(i)when included in Schedule 6 or 7;
(ii)in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;
(iii)in other divided preparations containing 30 micrograms or less of selenium per dosage unit;
(iv)as elemental selenium, in pellets containing 100 g/kg or less of selenium; or
(v) in feeds containing 1 g/tonne or less of selenium
SERMORELIN.
SERTINDOLE.
SERTRALINE.
SEVELAMER.
SEVOFLURANE.
SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.
SIBUTRAMINE.
SILANDRONE.
SILDENAFIL.
SILICONES for intra-ocular use.
SILVER SULFADIAZINE.
SIMVASTATIN.
SIROLIMUS.

SCHEDULE 4–continued
SISOMICIN (sisomycin).
SITAGLIPTIN.
SITAXENTAN.
SODIUM BROMIDE for therapeutic use.
SODIUM CELLULOSE PHOSPHATE for human internal use. SODIUM CROMOGLYCATE **except** when included in Schedule 2. SODIUM MORRHUATE in preparations for injection.
SODIUM NITROPRUSSIDE for human therapeutic use.
SODIUM PHOSPHATE in preparations for oral laxative use.
SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.
SODIUM SALICYLATE in preparations for injection for the treatment of animals. SODIUM TETRADECYLSULFATE in preparations for injection.
SOLASODINE.
SOLIFENACIN.
SOMATOSTATIN.
SOMATOTROPIN EQUINE.
SOMATROPIN (human growth hormone). SONTOQUINE.
SORAFENIB.
SOTALOL.

SPARFLOXACIN.
SPARTEINE.
SPECTINOMYCIN.
SPIRAMYCIN.

SCHEDULE 4–continued
SPIRAPRIL.
SPIRONOLACTONE.
#STANOLONE.
#STANOZOLOL.
STAVUDINE.
#STENBOLONE.
STEROID HORMONES **except** when separately specified in these Schedules.
STILBOESTROL (diethylstilboestrol).
STREPTODORNASE.
STREPTOKINASE.
STREPTOMYCIN.
STRONTIUM RANELATE.
STROPHANTHINS.
STROPHANTHUS spp.
STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.
STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.
STYRAMATE.
SULBACTAM.
SULCONAZOLE **except** when included in Schedule 2. SULFACETAMIDE **except** when included in Schedule 3 or 5. SULFADIAZINE **except** when included in Schedule 5.
SULFADIMETHOXINE.
SULFADIMIDINE **except** when included in Schedule 5.

SCHEDULE 4–continued
SULFADOXINE.
SULFAFURAZOLE.
SULFAGUANIDINE.
SULFAMERAZINE **except** when included in Schedule 5.
SULFAMETHIZOLE.
SULFAMETHOXAZOLE.
SULFAMETHOXYDIAZINE.
SULFAMETHOXYPYRIDAZINE.
SULFAMETROLE.
SULFAMONOMETHOXINE.
SULFAMOXOLE.
SULFAPHENAZOLE.
SULFAPYRIDINE.

SULFAQUINOXALINE.
SULFASALAZINE.
SULFATHIAZOLE **except** when included in Schedule 5.
SULFATROXAZOLE.
SULFINPYRAZONE.
SULFOMYXIN.
SULFONAMIDES **except**:
(a)when separately specified in this Schedule; or
(b)when included in Schedule 3, 5 or 6. SULFONMETHANE (sulfonal) and alkyl sulfonals. SULINDAC.

SCHEDULE 4–continued

SULTAMICILLIN.
SULTHIAME.
SUMATRIPTAN.
SUNITINIB.
SUPROFEN.
SUTILAINS.
SUXAMETHONIUM.
SUXETHONIUM.
TACRINE.
TACROLIMUS.
TADALAFIL.
TAMOXIFEN.
TAMSULOSIN.
TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil of tansy.
TASONERMIN.
TAZAROTENE.
TAZOBACTAM.
T-CELL RECEPTOR ANTIBODY.
TEGAFUR.
TEGASEROD.
TELITHROMYCIN.
TEICOPLANIN.
TELBIVUDINE.

SCHEDULE 4–continued

TELMISARTAN.
TEMAZEPAM.
TEMOZOLOMIDE.
TEMSIROLIMUS.
TENECTEPLASE.
TENIPOSIDE.
TENOFOVIR.
TENOXICAM.

TEPOXALIN.
TERAZOSIN.
TERBINAFINE **except**:
(a)when included in Schedule 2; or
(b)in preparations for dermal use for the treatment of tinea pedis.
TERBUTALINE **except** when included in Schedule 3.
TERFENADINE.
#TERIPARATIDE.
TERLIPRESSIN.
TERODILINE.
TEROPTERIN.
#TESTOLACTONE.
#TESTOSTERONE **except** when included in Schedule 6.
TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.
TETANUS TOXOID for human use.

SCHEDULE 4–continued

TETRABENAZINE.
TETRACOSACTRIN.
TETRACYCLINE **except** when included in Schedule 5.
TETRAETHYLAMMONIUM.
TETROXOPRIM.
#THALIDOMIDE.
THENYLDIAMINE.
THEOPHYLLINE **except** when included in Schedule 3. THEVETIA PERUVIANA.
THEVETIN.
THIACETARSAMIDE in preparations for the prevention or treatment of heart worm in dogs. THIAMBUTOSINE.
THIAZOSULFONE.
THIETHYLPERAZINE.
THIOACETAZONE.
THIOCARLIDE.
THIOGUANINE.
#THIOMESTERONE (tiomesterone).
THIOPENTONE.
THIOPROPAZATE.
THIOPROPERAZINE.
THIORIDAZINE.
THIOSTREPTON.

SCHEDULE 4–continued

THIOTEPA.
THIOTHIXENE.
THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less of thiourea.
THYMOXAMINE (includes thymoxamine hydrochloride).
THYROID **except** when separately specified in this Schedule.
THYROTROPHIN.
THYROXINE (includes thyroxine sodium).
TIAGABINE.
TIAMULIN.
TIAPROFENIC ACID.
TIARAMIDE.
TIBOLONE.
TICARCILLIN.
TICLOPIDINE.
TIEMONIUM.
TIENILIC ACID.
TIGECYCLINE.
TIGLOIDINE.
TILETAMINE.
TILMICOSIN.
TILUDRONIC ACID (includes disodium tiludronate).
TIMOLOL.

SCHEDULE 4–continued

TINIDAZOLE.
TINZAPARIN (includes tinzaparin sodium).
TIOCONAZOLE **except**:
(a)when included in Schedule 2 or 3; or
(b)in preparations for dermal use for the treatment of tinea pedis.
TIOTROPIUM.
TIPEPIDINE.
TIPRANAVIR.
TIRILAZAD.
TIROFIBAN.
TOBRAMYCIN.
TOCAINIDE.
TOLAZAMIDE.
TOLAZOLINE.
TOLBUTAMIDE.
TOLCAPONE. TOLFENAMIC ACID. TOLMETIN. TOLONIUM. TOLPROPAMINE. TOLRESTAT. TOLTERODINE. TOPIRAMATE. TOPOTECAN.

SCHEDULE 4–continued

TORASEMIDE.
TOREMIFENE.
TOXOIDS for human parenteral use **except** when separately specified in these

Schedules.
TRAMADOL.
TRANDOLAPRIL.
TRANEXAMIC ACID.
TRANYLCYPROMINE.
TRASTUZUMAB.
TRAVOPROST.
TRAZODONE.
#TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5. TREOSULPHAN.
TREPROSTINIL.
#TRESTOLONE.
TRETAMINE.
TRETINOIN.
TRIACETYLOLEANDOMYCIN.
TRIAMCINOLONE **except** when included in Schedule 2 or 3.
TRIAMTERENE.
TRIAZIQUONE.
TRIAZOLAM.
TRICHLORMETHIAZIDE.
TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

SCHEDULE 4–continued
TRICHLOROETHYLENE for therapeutic use.
TRICLOFOS.
TRICYCLAMOL.
TRIDIHEXETHYL.
TRIFLUOPERAZINE.
TRIFLUPERIDOL.
TRIFLUPROMAZINE.
TRILOSTANE.
TRIMEPRAZINE **except** when included in Schedule 2 or 3.
TRIMETAPHAN.
TRIMETHOPRIM.
TRIMIPRAMINE.
TRIMUSTINE.
TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use. TRIOXYSALEN.
TRIPELENNAMINE.
TRIPLE ANTIGEN VACCINE.
TRIPROLIDINE **except** when included in Schedule 2 or 3.
TRIPTORELIN.
TROGLITAZONE.
TROMETAMOL in preparations for injection **except** in preparations

containing 3 per cent or less of trometamol.
TROPICAMIDE.
TROPISETRON.

SCHEDULE 4–continued
TROVAFLOXACIN.
TROXIDONE.
TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.
TUBOCURARINE.
TULATHROMYCIN.
TULOBUTEROL.
TYLOSIN **except**:
(a)when included in Schedule 5;
(b)in animal feeds containing 50 mg/kg or less of antibiotic substances:
(i)for growth promotion;
(ii)for the prevention of liver abscesses in cattle; or
(iii)for the prevention of ileitis in pigs; or
(c)in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.
TYPHOID VACCINE.
UNOPROSTONE.
URACIL.
URAPIDIL.
URETHANE (excluding its derivatives) for therapeutic use.
UROFOLLITROPIN.
UROKINASE.
URSODEOXYCHOLIC ACID.
VACCINES for human therapeutic use **except** when separately specified in this Schedule.

SCHEDULE 4–continued
VACCINES, veterinary live virus **except**:
(a)poultry vaccines;
(b)pigeon pox vaccine; or
(c)scabby mouth vaccine. VALACICLOVIR. VALDECOXIB. VALGANCICLOVIR. VALNOCTAMIDE.
VALPROIC ACID. VALSARTAN. VANCOMYCIN. VARDENAFIL. VARENICLINE. VARICELLA VACCINE. VASOPRESSIN. VECURONIUM. VEDAPROFEN. VENLAFAXINE. VERAPAMIL.
VERATRUM spp. **except** when separately specified in this Schedule.
VERTEPORFIN.
VIDARABINE.
VIGABATRIN.

SCHEDULE 4–continued

VILDAGLIPTIN.
VILOXAZINE.
VINBLASTINE.
VINCAMINE.
VINCRISTINE.
VINDESINE.
VINORELBINE.
VINYL ETHER for therapeutic use.
VIRGINIAMYCIN **except** when included in Schedule 5.
VISNADINE.
VITAMIN A for human therapeutic or cosmetic use **except**:
(a)in preparations for topical use containing 1 per cent or less of vitamin A;
(b)in preparations for internal use containing 3000 micrograms retinol equivalents or less of vitamin A per daily dose; or
(c)in preparations for parenteral nutrition replacement.
VITAMIN D for human internal therapeutic use **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.
VORICONAZOLE.
WARFARIN for therapeutic use.
XAMOTEROL.
XANTHINOL NICOTINATE.
XIMELAGATRAN.
XIPAMIDE.
XYLAZINE.

SCHEDULE 4–continued

YOHIMBINE.
ZAFIRLUKAST.
ZALCITABINE.
ZALEPLON.
ZANAMIVIR.
ZERANOL **except** when included in Schedule 6.
ZIDOVUDINE.
ZILPATEROL.
ZIMELDINE.
ZINC COMPOUNDS for human internal use **except**:
(a)in preparations with a recommended daily dose of 25 mg or less of zinc; or
(b)in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.
ZIPRASIDONE.
ZOLAZEPAM.
ZOLEDRONIC ACID.
ZOLMITRIPTAN.
ZOLPIDEM.

ZONISAMIDE.
ZOPICLONE.
ZOXAZOLAMINE.
ZUCLOPENTHIXOL.

SCHEDULE 5

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH_3COOH) **except**:

(a)when included in Schedule 2 or 6; or

(b)for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a)in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is more than 11.5;

(b)in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;

(c)in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(d)in liquid or semi-solid preparations the pH of which is more than 11.5,

except when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing

50 per cent or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

SCHEDULE 5–continued

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

(a)in insecticidal mats; or

(b)in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

(a)in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or

(b)in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.
AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.
AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.
AMITROLE.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:
(a)in preparations for human internal therapeutic use;
(b)in preparations for inhalation when absorbed in an inert solid material; or
(c)in preparations containing 0.5 per cent or less of free ammonia.
AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.
ANHYDRIDES, ORGANIC ACID, for use as curing agents for epoxy resins **except** when separately specified in these Schedules.
ANISE OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5–continued
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 50 per cent or less of anise oil.
ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.
ATRAZINE.
† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.
AZOXYSTROBIN.
BACILLUS THURINGIENSIS DELTA ENDOTOXIN encapsulated in killed *Pseudomonas fluorescens*.
BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq.cm.
BASIL OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 5 per cent or less of methyl chavicol.
BEAUVERIA BASSIANA in preparations containing 1 x 10^8 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.
BENALAXYL.
BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

SCHEDULE 5–continued

BENTAZONE.
BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.
BENZOFENAP.
BENZOYL PEROXIDE **except**:
(a)when included in Schedule 2 or 4; or
(b)in preparations containing 5 per cent or less of benzoyl peroxide.
BERGAMOT OIL **except**:
(a)when steam distilled or rectified;
(b)in preparations for internal use;
(c)in preparations containing 0.4 per cent or less of bergamot oil;
(d)in soaps or bath or shower gels that are washed off the skin;
(e)in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(f) in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight.
BETACYFLUTHRIN:
(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or
(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.
BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 0.3 per cent or less of total bifluorides.
BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.
BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

SCHEDULE 5–continued

BORIC ACID (excluding its salts) and BORAX **except**:
(a)when included in Schedule 4;
(b)in preparations, other than insect baits, containing 1 per cent or less of boron; or
(c) in hand cleaning preparations.
BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF_3).
BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole. BUPROFEZIN **except** in preparations containing 40 per cent

or less of buprofezin. BUTHIDAZOLE.
BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.
BUTRALIN.
BUTROXYDIM.
CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:
(a)in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(c)in rosemary oil, sage oil (Spanish), or lavandin oils; or
(d)in preparations containing 2.5 per cent or less of camphor.
CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

SCHEDULE 5–continued
CARBARYL:
(a)in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or
(b)when impregnated into plastic resin material containing 20 per cent or less of carbaryl.
CASSIA OIL **except**:
(a)in food additives; or
(b)in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or
(c)in other preparations containing 2 per cent or less of cassia oil.
CHLORFENAC.
CHLORFENSON.
CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except**:
(a)in preparations containing 1 per cent or less of chlorhexidine; or
(b)when in solid preparations.
CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except**:
(a)when separately specified in these Schedules;
(b)sodium hypochlorite preparations with a pH of less than 11.5;
(c)liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(d)liquid preparations containing less than 2 per cent of available chlorine; or

(e)other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

SCHEDULE 5–continued

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a)in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;

(b)in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or

(c)in other preparations containing 5 per cent or less of chlorpyrifos,

except in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a)for topical application to animals for ocular use only; or

(b)containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a)in food additives; or

(b)in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

SCHEDULE 5–continued

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate **except** in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide **except** in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides **except**:
(a)in preparations for internal use;
(b)in marine paints; or
(c)in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride **except** in preparations containing 12.5 per cent or less of copper oxychloride.
COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate **except**:
(a)in preparations for internal use; or
(b)in other preparations containing 5 per cent or less of copper sulfate.
COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl. 4-CPA.
CYANATRYN.

SCHEDULE 5–continued

CYANOACRYLATE ESTERS in contact adhesives **except**:
(a)when labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or
(b)when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:
(i)labelled with the approved name or trade name of the poison, the quantity and the warning:
Can cause eye injury. Instantly bonds skin; and
(ii)enclosed in a primary pack labelled with the warning:
KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately sh with water.
CYANURIC ACID (excluding its salts and derivatives).
CYCLOHEXANONE PEROXIDE.
CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.
CYCLOXYDIM.
CYFLUTHRIN:
(a) in wettable powders containing 10 per cent or less of cyfluthrin;
(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or
(c) in emulsions containing 5 per cent or less of cyfluthrin.
CYHALOFOP-BUTYL.
CYMIAZOLE.

SCHEDULE 5–continued

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin. CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin. CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole. CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

(a)in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or

(b)in undivided preparations containing 5 per cent or less of cythioate.

2,4-D in preparations containing 20 per cent or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DELTAMETHRIN:

(a)in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;

(b)in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 g or less of the formulation;

(c)in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or

(d)in other preparations containing 0.5 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 5–continued

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

(a)liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(b)liquid preparations containing less than 2 per cent of available chlorine; or

(c)other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a)in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;
(b)in other preparations in pressurised spray packs; or
(c)in paints and tinters containing 5 per cent or less of dichloromethane.
DICHLOROPHEN for the treatment of animals.
DICHLORVOS:
(a)when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;
(b)in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or
(c)in pressurised spray packs containing 10 grams or less of dichlorvos.
DICLOBUTRAZOL.
DICLORAN.

SCHEDULE 5–continued

DICOFOL.
DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing
5 per cent or less of diethanolamine.
DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.
DIETHYLTOLUAMIDE (DEET) **except**:
(a)in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:
WARNING: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or
(c)in preparations other than for human use containing 20 per cent or less of diethyltoluamide.
DIFENOCONAZOLE.
DIFLUBENZURON.
DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.
DIMETHIRIMOL.
DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.
DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.
DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

SCHEDULE 5–continued
DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.
DIPHENAMID.
DITHIOPYR.
N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N- dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N- octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.
DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.
EMAMECTIN in preparations containing 2 per cent or less of emamectin.
EMODEPSIDE in preparations containing 2.5 per cent or less of emodepside for external treatment of animals.
ENILCONAZOLE.
EPOXICONAZOLE.
EPOXY RESINS, LIQUID.
EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.
ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.
1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.
ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:
(a)when included in Schedule 4; or
(b)in preparations containing 5 per cent or less of ethanolamine.
ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.
ETHOFUMESATE.
Federal Register of Legislative Instruments F2009L03012
SCHEDULE 5–continued
ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.
ETHOXYSULFURON.
ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:
(a)in paints or paint tinters; or
(b)in other preparations containing 2.5 per cent or less of ethylene glycol.
ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use

except in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.
ETRIDIAZOLE.
EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.
EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*), **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.
FENARIMOL.
FENBENDAZOLE for the treatment of animals.
FENBUCONAZOLE.
FENCHLORAZOLE-ETHYL.
FENOPROP.
FENOXAPROP-ETHYL.
FENOXAPROP-P-ETHYL.
FENSON.
FENTHION:
(a)in preparations containing 25 per cent or less of fenthion when packed in single- use containers having a capacity of 2 mL or less; or
(b)in preparations containing 10 per cent or less of fenthion.

SCHEDULE 5–continued
FIPRONIL in preparations containing 10 per cent or less of fipronil except in preparations containing 0.05 per cent or less of fipronil.
FLAMPROP-METHYL.
FLAMPROP-M-METHYL.
FLORASULAM.
FLUAZURON.
FLUBENDAZOLE for the treatment of animals.
FLUBENDIAMIDE.
FLUCHLORALIN.
FLUDIOXONIL except in preparations containing 10 per cent or less of fludioxonil.
FLUMETHRIN:
(a)when impregnated in plastic resin strip material containing 3 per cent or less of flumethrin; or
(b)in oil based preparations containing 1 per cent or less of flumethrin. FLUMICLORAC PENTYL.
FLUORIDES in preparations containing 3 per cent or less of fluoride ion except in preparations:
(a)for human use; or
(b)containing 15 mg/kg or less of fluoride ion.
FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.
FORMIC ACID (excluding its salts and derivatives) **except** in preparations

containing 0.5 per cent or less of formic acid.
FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.
FURALAXYL.
FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

SCHEDULE 5–continued
GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.
GLUFOSINATE-AMMONIUM.
GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:
(a)when included in Schedule 2; or
(b)in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:
IRRITANT; and
Avoid contact with eyes.
GLYPHOSATE.
HALOSULFURON-METHYL.
HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.
HEXAZINONE in preparations containing 25 per cent or less of hexazinone.
HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.
HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:
(a)toluene and xylene when included in Schedule 6;
(b)benzene and liquid aromatic hydrocarbons when included in Schedule 7;
(c)food grade and pharmaceutical grade white mineral oils;
(d)in solid or semi-solid preparations;
(e)in preparations containing 25 per cent or less of designated solvents;
(f)in preparations packed in pressurised spray packs;
(g)in adhesives packed in containers each containing 50 grams or less of adhesive;

SCHEDULE 5–continued
(h)in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or
(i)in other preparations when packed in containers with a capacity of 2 mL or less.
HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:
(a)in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or
(b)for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.
HYDROGEN PEROXIDE (excluding its salts and derivatives):
(a)in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or
(b)in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent
(10 volume) or less of hydrogen peroxide.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H_2SiF_6).
IMAZALIL.
IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.
IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.
IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.
IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.
IMIDACLOPRID in preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

SCHEDULE 5–continued
IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.
INDOXACARB (Includes the R and S enantiomers) in preparations containing 1 per cent or less of indoxacarb.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except** in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.
IODOSULFURON-METHYL-SODIUM.
IRON COMPOUNDS:
(a)for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):
(i)in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or
(ii)in other preparations containing 4 per cent or less of iron **except**:
(A)in liquid or gel preparations containing 0.1 per cent or less of iron; or
(B)in animal feeds or feed premixes; or
(b)in garden preparations **except** in preparations containing 4 per cent or less of iron.
ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.
ISOPHORONE.
ISOXABEN.

ISOXAFLUTOLE.
IVERMECTIN for use in animals:
(a)in preparations for the prophylaxis of heartworm in cats and dogs;
(b)in intraruminal implants containing 160 mg or less of ivermectin;

SCHEDULE 5–continued

(c)in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or
(d)in other preparations containing 2 per cent or less of ivermectin.
KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
LAMBDA-CYHALOTHRIN:
(a)in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or
(b)in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.
†LEAD COMPOUNDS in preparations for use as hair cosmetics.
LEMON OIL **except**:
(a)when steam distilled or rectified;
(b)in preparations for internal use;
(c)in preparations containing 0.05 per cent or less of lemon oil;
(d)in soaps or bath or shower gels that are washed off the skin;
(e)in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(f)in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight.
LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except**:
(a)when included in Schedule 4; or
(b)in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

SCHEDULE 5–continued

LIME OIL **except**:
(a)when steam distilled or rectified;
(b)in preparations for internal use;
(c)in preparations containing 0.5 per cent or less of lime oil;
(d)in soaps or bath or shower gels that are washed off the skin;
(e)in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(f)in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight.
LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON **except**:
(a)in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or
(b)in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.
MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.
MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.
MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.
MALATHION in preparations containing 10 per cent or less of malathion **except**:
(a)for human therapeutic use; or
(b)in dust preparations containing 2 per cent or less of malathion.
MANCOZEB.

SCHEDULE 5–continued
MARJORAM OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 50 per cent or less of marjoram oil.
MCPA
(a)in preparations containing 25 per cent or less of MCPA (acid); or
(b)in preparations containing 50 per cent or less of the salts and esters of MCPA.
MCPB.
MEBENDAZOLE for the treatment of animals:
(a)in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or
(b)in undivided preparations containing 25 per cent or less of mebendazole.
MECLOFENAMIC ACID for the treatment of animals.
MECOPROP in preparations containing 2 per cent or less of mecoprop.
MEFENPYR-DIETHYL.
MEPIQUAT.
METAFLUMIZONE.
METALAXYL in preparations containing 35 per cent or less of metalaxyl.
METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.
METHABENZTHIAZURON.

SCHEDULE 5–continued

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a)when included in preparations or admixtures; or

(b)when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

(a)when packed in single use containers having a capacity of 2 mL or less; or

(b)in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N- methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing
25 per cent or less of designated solvents.

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate **except**:

(a)in preparations for therapeutic use; or

(b)in preparations containing 5 per cent or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

Federal Register of Legislative Instruments F2009L03012

SCHEDULE 5–continued

METIRAM.

METOLACHLOR.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

(a)in preparations for external use for the treatment of animals other than cats

and dogs, containing 0.5 per cent or less of moxidectin;
(b)in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or
(c)for internal use for the treatment of animals:
(i)in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or
(ii)in other preparations containing 2 per cent or less of moxidectin.
MYCLOBUTANIL.
NAA **except** in preparations containing 25 per cent or less of NAA.
NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.
NAPTALAM.
NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.
NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO_3) **except** in preparations containing 0.5 per cent or less of nitric acid.

SCHEDULE 5–continued

NITROSCANATE for the treatment of animals.
NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:
(a)when labelled with the statements: IRRITANT; and
Avoid contact with eyes;
(b)in preparations containing 12.5 per cent or less of nonoxinol 9; or
(c)in preparations for human use.
NORBORMIDE.
NUTMEG OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 50 per cent or less of nutmeg oil.
N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of N-octyl bicycloheptene dicarboximide.
N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N- dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.
OESTRADIOL in implant preparations for growth promotion in animals.

OLEANDOMYCIN in animal feed premixes for growth promotion.
OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

SCHEDULE 5–continued

ORANGE OIL (BITTER) **except**:
(a)when steam distilled or rectified;
(b)in preparations for internal use;
(c)in preparations containing 1.4 per cent or less of orange oil (bitter);
(d)in soaps or bath or shower gels that are washed off the skin;
(e)in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(f)in other preparations when packed in containers labelled with the statement: Application to the skin may increase sensitivity to sunlight. OXADIARGYL.
OXADIXYL.
OXANTEL EMBONATE for the treatment of animals.
OXFENDAZOLE for the treatment of animals.
OXIBENDAZOLE for the treatment of animals.
OXYCARBOXIN.
OXYTETRACYCLINE in preparations:
(a)for topical application to animals for ocular use only; or
(b)containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
OXYTHIOQUINOX.
PACLOBUTRAZOL.
PENCONAZOLE.
PENDIMETHALIN.
PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

SCHEDULE 5–continued

PERMETHRIN (excluding preparations for human therapeutic use):
(a)in preparations containing 25 per cent or less of permethrin; or
(b)in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,
except in preparations containing 2 per cent or less of permethrin.
PETROL **except** preparations containing 25 per cent or less of petrol.
PHENAZONE for the external treatment of animals.
PHENISOPHAM.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.
PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.
ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less

of o-phenylphenol.
PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H_3PO_3).
PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H_3PO_4) **except**:
(a)in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
(b)in solid or semi-solid preparations; or
(c)in professional dental kits.
ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.
PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.
PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

SCHEDULE 5–continued

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.
PIPERAZINE for animal use.
PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.
POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.
POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts **except** in preparations containing 1 per cent or less of polixetonium salts.
POLYETHANOXY (15) TALLOW AMINE.
POLY(OXY-1,2-ETHANEDIYL), -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- -
HYDROXY-,MONO-C_{13-15}-ALKYL ETHERS.
POTASSIUM CHLORATE **except**:
(a)when included in Schedule 2; or
(b)in preparations containing 10 per cent or less of potassium chlorate.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:
(a)solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b)liquid or semi-solid preparations the pH of which is more than 11.5.
POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.
POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite **except**:
(a)in preparations containing 0.5 per cent or less of potassium nitrite;
(b)when present as an excipient in preparations for therapeutic use; or
(c)in aerosols.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
(a)solid preparations the pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b)liquid or semi-solid preparations the pH of which is less than 2.5.

SCHEDULE 5–continued

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.
PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.
PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.
PROGESTERONE:
(a)in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or
(b)in implant preparations for growth promotion in cattle.
PROHEXADIONE CALCIUM.
PROMETRYN.
PROPAMOCARB.
PROPANIL.
PROPAQUIZAFOP.
PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.
PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:
(a)in preparations containing 30 per cent or less of propionic acid; or
(b)for therapeutic use.
PROPOXUR:
(a)when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;
(b)in dust preparations containing 3 per cent or less of propoxur;
(c)in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;
(d)in pressurised spray packs containing 10 g or less of propoxur; or
(e)in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

SCHEDULE 5–continued

PROPYZAMIDE.
PYMETROZINE.
PYRACLOSTROBIN.
PYRAFLUFEN-ETHYL.
PYRASULFOTOLE.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids **except**:
(a)in preparations for human therapeutic use; or
(b)in preparations containing 10 per cent or less of such substances.
PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:
(a)when separately specified in these Schedules;
(b)dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
(c)in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of quizalofop- p-ethyl.

SCHEDULE 5–continued

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine. RESMETHRIN in preparations containing 10 per cent or less of resmethrin. RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SALICYLANILIDE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:
(a)barium silicofluoride when separately specified in this Schedule; or
(b)in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin **except** in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per

cent or less of sodium hydrogen sulfate.
SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.
SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:
(a)solid preparations the pH of which in a 10 g/L aqueous solution is more than 11.5; or
(b)liquid or semi-solid preparations the pH of which is more than 11.5.

SCHEDULE 5–continued

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.
SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.
SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except**:
(a)in preparations containing 0.5 per cent or less of sodium nitrite;
(b)when present as an excipient in preparations for therapeutic use; or
(c)in aerosols.
SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing
35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.
SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.
SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.
SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.
SPINETORAM.
SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.
STAR ANISE OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 50 per cent or less of star anise oil.

SCHEDULE 5–continued

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H_3NO_3S).
SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.
SULFOMETURON-METHYL.
† SYMPHYTUM spp. (Comfrey) for dermal use.
2,3,6-TBA.
TDE (1,1-dichloro-2,2-bis [4-chlorophenyl] ethane) in preparations containing 10 per cent or less of TDE.
TEBUCONAZOLE.
TEBUFENOZIDE.
TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.
TEMEPHOS:
(a)in liquid preparations containing 10 per cent or less of temephos;
(b)in powders containing 2 per cent or less of temephos; or
(c)in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.
TEPRALOXYDIM.
TERBUTRYN.

SCHEDULE 5–continued

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:
(a)when included in Schedule 2;
(b)in preparations for the treatment of animals; or
(c)when absorbed into an inert solid.
TETRACHLORVINPHOS **except** in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.
TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole. TETRACYCLINE in preparations:
(a)for topical application to animals for ocular use only; or
(b)containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.
TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.
THIABENDAZOLE:
(a)for the treatment of animals; or
(b)when packed and labelled for use as a fungicide **except** in preparations

containing 50 per cent or less of thiabendazole.
THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.
THIAZOPYR.
THIFENSULFURON.
THIOBENCARB.
THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.
THYME OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 5–continued
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:
KEEP OUT OF REACH OF CHILDREN; or
(c)in preparations containing 50 per cent or less of thyme oil.
TIOCARBAZIL.
TOLCLOFOS-METHYL.
TOLTRAZURIL.
TRALKOXYDIM.
TRENBOLONE in implant preparations for growth promotion in animals.
TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon. TRIADIMENOL.
TRI-ALLATE.
TRIBENURON-METHYL.
TRICHLOROACETIC ACID, alkali salts of.
†1,1,1-TRICHLOROETHANE **except**:
(a)in preparations packed in pressurised spray packs;
(b)in preparations containing 25 per cent or less of designated solvents;
(c)in preparations, other than writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less; or
(d)in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:
(i)the word “Trichloroethane” written in letters not less than
1 mm in height and in distinct contrast to the background; and

SCHEDULE 5–continued
(ii)the expression:
WARNING - DO NOT DELIBERATELY SNIFF THIS PRODUCT.
SNIFFING MIGHT HARM OR KILL YOU;
written in bold face sanserif capital letters not less than
1 mm in height and in distinct contrast to the background.

TRIDIPHANE.
TRIETAZINE.
TRIETHANOLAMINE (excluding its salts and derivatives) **except** in preparations containing 5 per cent or less of triethanolamine.
TRIFLOXYSTROBIN.
TRIFLUMIZOLE.
TRIFLUMURON.
TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:
Avoid contact with eyes and skin; and
Wash hands after handling.
TRINEXAPAC-ETHYL **except**:
(a)when packed in a sealed water-soluble measure pack; or
(b)in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.
3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of 3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.
TRITICONAZOLE.
TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

SCHEDULE 5–continued

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:
(a)for growth promotion;
(b)for the prevention of liver abscesses in cattle; or
(c)for the prevention of ileitis in pigs.
VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.
VERNOLATE.
WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.
ZINEB.

SCHEDULE 6

(Substances marked † are listed in Appendix C)
ABAMECTIN:
(a)in preparations for pesticidal use containing 2 per cent or less of abamectin **except** when included in Schedule 5; or
(b)in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.
ACEPHATE.
ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH_3COOH) **except** when included in Schedule 2.
ACETIC ANHYDRIDE excluding its derivatives.
ACIFLUORFEN.
ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.
ALBENDAZOLE for the treatment of animals **except:**
(a)when included in Schedule 5; or
(b)in intraruminal implants each containing 3.85 g or less of albendazole.
ALDRIN.
†ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:
(a)in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or
(b)in liquid or semi-solid automatic dishwashing preparations the pH of which is more than 12.5.
ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

SCHEDULE 6–continued
ALLETHRIN **except**:
(a)when included in Schedule 5;
(b)in insecticidal mats containing 20 per cent or less of allethrin; or
(c)in other preparations containing 1 per cent or less of allethrin.
ALPHA-CYPERMETHRIN:
(a)in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or
(b)in other preparations containing 10 per cent or less of alpha-cypermethrin,
except when included in Schedule 5. AMICARBAZONE.
AMIDITHION.
AMINOCARB in preparations containing 25 per cent or less of aminocarb.
AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.
1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.
AMINOPYRALID.
AMITRAZ.
AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:
(a)when included in Schedule 5;
(b)in preparations for human internal therapeutic use;
(c)in preparations for inhalation when absorbed in an inert solid material; or
(d)in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.
ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

SCHEDULE 6–continued
ANTIMONY COMPOUNDS **except**:
(a)when included in Schedule 4;
(b)antimony chloride in polishes;
(c)antimony titanate pigments in paint; or
(d)in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.
ARSENIC:
(a)in ant poisons containing 0.4 per cent or less of arsenic;
(b)in animal feed premixes containing 4 per cent or less of arsenic; or
(c)in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,
except when separately specified in this Schedule.
ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5. AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole.
†AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:
(a)when included in Schedule 5;
(b)in preparations for human internal use;
(c)debitterised neem seed oil;
(d)in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or
(e)in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.
AZAMETHIPHOS.
AZOBENZENE.

SCHEDULE 6–continued
BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.
BARIUM SALTS **except**:
(a)when included in Schedule 5;
(b)barium sulfate; or
(c)in paints or tinters containing 5 per cent or less of barium calculated on the non- volatile content of the paint or tinter.
†BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except**:
(a)in preparations for skin colouration and dyeing of eyelashes or eyebrows; or
(b)in hair dye preparations containing 1 per cent or less of Basic Orange 31

when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN;
If in eyes wash out immediately with water; and
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height.
BAY OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

SCHEDULE 6–continued
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(e)in preparations containing 25 per cent or less of bay oil.
BEAUVERIA BASSIANA **except** when included in Schedule 5.
BENDIOCARB:
(a)in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;
(b)in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;
(c)in insoluble granular preparations containing 5 per cent or less of bendiocarb; or
(d)when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

except when included in Schedule 5. BENQUINOX.
BENSULIDE.
BENZALKONIUM CHLORIDE **except**:

(a)when included in Schedule 5; or
(b)in preparations containing 5 per cent or less of benzalkonium chloride.

SCHEDULE 6–continued

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.
BERYLLIUM.
BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.
BETA-CYPERMETHRIN.
BHC (excluding lindane).
BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin **except** in preparations containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.
BIOALLETHRIN **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 1 per cent or less of bioallethrin.
N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)- bicyclo-(2.2.1)heptane-2,5-dimethanamine, or a combination of N,N- bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N- bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
Federal Register of Legislative Instruments F2009L03012

SCHEDULE 6–continued

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)- bicyclo-(2.2.1)heptane-2,6-dimethanamine, or a combination of N,N- bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and N,N- bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:
IRRITANT;
REPEATED EXPOSURE MAY CAUSE SENSITISATION;
Avoid contact with eyes;
Avoid contact with skin;
Wear protective gloves when mixing or using; and
Ensure adequate ventilation when using.
† BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron **trifluoride (BF_3) except when included in Schedule 5.**
BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.
BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.
BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.
BROMOFORM **except** when included in Schedule 4.
BROMOPHOS.
BROMOPHOS-ETHYL.
BROMOXYNIL.
BROMUCONAZOLE **except** when included in Schedule 5.
BROTIANIDE.
BUNAMIDINE.
BUTACARB.
BUTOXYCARBOXIM **except** when included in Schedule 5.
2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

SCHEDULE 6–continued
2-BUTOXY-2'-THIOCYANO-DIETHYL ETHER.
BUTYRIC ACID in preparations for use as insect lures.
CACODYLIC ACID:
(a)in animal feed premixes containing 4 per cent or less of arsenic; or
(b)in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.
CADMIUM COMPOUNDS **except**:
(a)when included in Schedule 4; or
(b)in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.
CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.
CAJUPUT OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;

(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;

SCHEDULE 6–continued
(e)in preparations containing 25 per cent or less of cajuput oil; or
(f)in oils containing 25 per cent or less of cajuput oil. CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol. CAMBENDAZOLE.
CAMPHOR **except**:
(a)when included in Schedule 4 or 5;
(b)when enclosed in an inhaler device which prevents ingestion of its contents;
(c)in solid or semi-solid preparations containing 12.5 per cent or less of camphor;
(d)in liquid preparations containing 2.5 per cent or less of camphor;
(e)in essential oils when the camphor is present as a natural component of the oil:
(i)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(ii)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(iii)in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and
NOT TO BE TAKEN; or

SCHEDULE 6–continued
(iv)in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(f)in rosemary oil, sage oil (Spanish), or lavandin oil as such.
CAPTAN.
CARBARYL **except** when included in Schedule 4 or 5.
CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.5 per cent or less of carbendazim.
CARBON DISULFIDE.
CARBAMIDE PEROXIDE **except**:
(a)when included in Schedule 5; or

(b)in other preparations containing 9 per cent or less of carbamide peroxide.
CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.
CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.
CHLORDANE.
CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr.
CHLORFENETHOL.
CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:
(a)when included in Schedule 5;
(b)in preparations containing 1 per cent or less of chlorhexidine; or
(c)when in solid preparations.

SCHEDULE 6–continued

CHLORINATING COMPOUNDS **except**:
(a)when included in Schedule 5;
(b)when separately specified in these Schedules;
(c)sodium hypochlorite preparations with a pH of less than 11.5;
(d)in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:
WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;
(e)in liquid preparations containing less than 2 per cent of available chlorine; or
(f)in other preparations containing 4 per cent or less of available chlorine. CHLORMEQUAT.
CHLOROFORM **except**:
(a)when included in Schedule 2 or 4; or
(b)in preparations containing 10 per cent or less of chloroform. alpha-CHLOROHYDRIN.
CHLOROPHACINONE.
(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN- 3-OL (uniconazole-p) **except** in preparations containing 5 per cent or less of (E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1- yl)pent-1-en-3-ol.
CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.
CHLOROTHALONIL **except** in water-based paint containing 0.5 per cent or less of chlorothalonil.
CHLORPYRIFOS **except**:
(a)when included in Schedule 5; or
(b)in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

SCHEDULE 6–continued

CHLORPYRIFOS-METHYL.
CHLORTHIAMID.
CHROMATES (including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.
CHROMIUM TRIOXIDE (excluding its salts and derivatives).
CINEOLE **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(e)in preparations containing 25 per cent or less of cineole;
(f)in oils containing 25 per cent or less of cineole; or
(g)in rosemary oil or camphor oil (white).

SCHEDULE 6–continued

CINNAMON LEAF OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a

restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(e)in preparations containing 25 per cent or less of cinnamon leaf oil.
CLIMBAZOLE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 2 per cent or less of climbazole.
CLODINAFOP-PROPARGYL.
CLOMAZONE.
CLOSANTEL.
CLOTHIANIDIN **except** when included in Schedule 5.
CLOTRIMAZOLE for external treatment of animals.

SCHEDULE 6–continued
CLOVE OIL **except**:
(a)when included in Schedule 5;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(e)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(f)in preparations containing 25 per cent or less of clove oil.
N-COCO-1,3-DIAMINOPROPANE.
COPPER ACETATE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 5 per cent or less of copper acetate.
COPPER COMPOUNDS **except**:
(a)when separately specified in these Schedules;
(b)in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

SCHEDULE 6–continued
(c)pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;

(d)in feed additives containing 1 per cent or less of copper; or
(e)in other preparations containing 5 per cent or less of copper compounds.
COPPER HYDROXIDE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 12.5 per cent or less of copper hydroxide.
COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.
COPPER OXIDES **except**:
(a)when included in Schedule 5;
(b)in preparations for internal use;
(c)in marine paints; or
(d)in other preparations containing 5 per cent or less of copper oxides.
COPPER OXYCHLORIDE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 12.5 per cent of less of copper oxychloride.
COPPER SULFATE **except**:
(a)when included in Schedule 5;
(b)in preparations for internal use; or
(c)in other preparations containing 5 per cent or less of copper sulfate.
COUMAPHOS
(a)in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or
(b)in other preparations containing 5 per cent or less of coumaphos.

SCHEDULE 6–continued

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl **except** when included in Schedule 5.
CREOSOTE derived from wood other than beechwood **except**:
(a)when included in Schedule 2;
(b)in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or
(c)in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.
CROTOXYPHOS.
CRUFOMATE.
CYANAMIDE.
CYANAZINE.
CYCLANILIDE.
N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM.
CYFLUTHRIN except:
(a)when included in Schedule 5; or
(b)in pressurised spray packs containing 1 per cent or less of cyfluthrin.
CYOMETRINIL.
CYPERMETHRIN **except** when included in Schedule 5.
CYPHENOTHRIN **except** when included in Schedule 5.
CYSTEAMINE for cosmetic use **except**:

(a)when included in Schedule 5; or

(b)in preparations containing 1 per cent or less of cysteamine. CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5. DAZOMET.

SCHEDULE 6–continued

DELTAMETHRIN:

(a)in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;

(b)in wettable granular preparations containing 25 per cent or less of deltamethrin;

(c)in water-dispersible tablets each containing 500 mg or less of deltamethrin;

(d)in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or

(e)in other preparations containing 3 per cent or less of deltamethrin,

except when included in Schedule 5. DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5. DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID. ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER. DICHLOROISOCYANURIC ACID **except**:

(a)when included in Schedule 5;

(b)in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

WARNING – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(c)in liquid preparations containing less than 2 per cent of available chlorine; or

(d)in other preparations containing 4 per cent or less of available chlorine.

SCHEDULE 6–continued

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

(a)when included in Schedules 4 or 5; or

(b)in fabrics other than when:

(i)for human therapeutic use; or

(ii)as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations

containing
1 per cent or less of didecyldimethylammonium salts labelled with the statement: Avoid contact with eyes.
DIELDRIN.
DIETHANOLAMINE (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 5 per cent or less of diethanolamine.
DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum. DIFENZOQUAT.
DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.
† 5,6-DIHYDROXYINDOLINE.
DIMETHENAMID-P.
DIMETHIPIN.
DIMETHOATE.

SCHEDULE 6–continued

DIMETHYLACETAMIDE **except** when included in Schedule 5.
DIMETHYLFORMAMIDE **except**:
(a)when included in Schedule 5; or
(b)in silicone rubber mastic containing 2 per cent or less of dimethylformamide. DIMETHYL SULFOXIDE:
(a)when not for therapeutic use; or
(b)for the treatment of animals:
(i)when combined with no other therapeutic substance(s);
(ii)in liquid preparations containing copper salicylate and
1 per cent or less of methyl salicylate as the only other therapeutic substances; or
(iii)in clay poultices containing 2 per cent or less of dimethyl sulfoxide.
DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:
(a)when included in Schedule 4; or
(b)when separately specified in this Schedule.
DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:
(a)when included in Schedule 4; or
(b)when separately specified in this Schedule. DIOXACARB.
DIOXANE.
DIPHACINONE.
DIQUAT in preparations containing 20 per cent or less of diquat.

SCHEDULE 6–continued

DISULFIRAM **except** when included in Schedule 4.
DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.
DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.
DIUREDOSAN.
N-(N-DODECYL)-2-PYRROLIDONE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 25 per cent or less of designated solvents.
DODINE.
DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.
DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.
ECONAZOLE for external treatment of animals.
EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.
EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.
ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.
ENDOTHAL in preparations containing 20 per cent or less of endothal.
EPTC.
ESBIOTHRIN **except**:
(a)when included in Schedule 5; or
(b)in pressurised spray packs containing 1 per cent or less of esbiothrin.
ESFENVALERATE **except** when included in Schedule 5.

SCHEDULE 6–continued

ETHANOLAMINE (excluding its salts and derivatives) **except**:
(a)when included in Schedule 4 or 5; or
(b)in preparations containing 5 per cent or less of ethanolamine.
ETHEPHON (excluding its salts and derivatives).
ETHER **except**:
(a)when included in Schedule 2, 4 or 5; or
(b)in preparations containing 10 per cent or less of ether.
ETHIOFENCARB.
ETHOATE-METHYL.
ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.
ETHYL BROMIDE.
ETHYL FORMATE when packed and labelled for use as a fumigant.
ETHYLENE CHLOROHYDRIN.
ETHYLENE DICHLORIDE.
ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5;
(b)in paints or paint tinters; or
(c)in preparations containing 2.5 per cent or less of ethylene glycol.
ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES,

except:
(a)when separately specified in these Schedules; or
(b)in preparations containing 10 per cent or less of such substances.
ETRIMFOS.

SCHEDULE 6–continued
EUCALYPTUS OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(e)in preparations containing 25 per cent or less of eucalyptus oil.
EUGENOL **except**:
(a)when included in Schedule 5;
(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;

SCHEDULE 6–continued
(e)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or

(f)in preparations containing 25 per cent or less of eugenol.
FAMPHUR in preparations containing 20 per cent or less of famphur.
FEBANTEL **except**:
(a)in divided preparations containing 1000 mg or less of febantel per dosage unit; or
(b)in undivided preparations containing 10 per cent or less of febantel.
FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos. FENAZAFLOR.
FENBUTATIN OXIDE. FENCHLORPHOS. FENITROTHION.
FENOXACRIM in preparations for the treatment of carpets during manufacture. FENPYROXIMATE.
FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.
FENVALERATE.
FIPRONIL **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 0.05 per cent or less of **fipronil.**
FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen**. FLUAZIFOP-BUTYL.**

SCHEDULE 6–continued

FLUAZIFOP-P-BUTYL.
FLUAZINAM.
FLUCOFURON in preparations for the treatment of carpets during manufacture. FLUMETHRIN except when included in Schedule 5.
FLUORIDES except:
(a)when included in Schedule 5;
(b)in preparations for human use; or
(c)in preparations containing 15 mg/kg or less of fluoride ion.
FLUPROPANATE.
FLUQUINCONAZOLE.
FLUSILAZOL.
FLUTRIAFOL except in fertilisers containing 0.5 per cent or less of flutriafol. FLUVALINATE except when included in Schedule 5.
†FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:
(a)for human therapeutic use;
(b)in oral hygiene preparations;
(c)in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;
(d)in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
(e)in all other cosmetic preparations; or

(f)in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.

SCHEDULE 6–continued
FORMOTHION.
FOSPIRATE **except** when included in Schedule 5.
FUMAGILLIN.
GLUTARALDEHYDE **except**:
(a)when included in Schedule 2 or 5; or
(b)in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:
IRRITANT; and
Avoid contact with eyes.
GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:
Wear protective gloves when using. Keep out of eyes.
GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:
(a)in cosmetic preparations for salon use only which are labelled in accordance with the *National Occupational Health and Safety Commission's National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012 (1994)];
(b)in preparations containing 5 per cent or less of glycolic acid; or
(c)in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.
GUAZATINE.
HALOXON.
HALOXYFOP.
HEPTACHLOR.
HEXACHLOROPHANE in preparations for the treatment of animals.
HEXAZINONE **except** when included in Schedule 5.

SCHEDULE 6–continued
HYDRAMETHYLNON **except** when included in Schedule 5.
HYDRAZINE.
HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5;
(b)in preparations for therapeutic use; or
(c)in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).
HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride except when included in Schedule 5.
HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a)when included in Schedule 5;
(b)in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or
(c)in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.
HYDROQUINONE **except**:
(a)when included in Schedule 2 or 4; or
(b)in preparations containing 10 per cent or less of hydroquinone.
HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H_2SiF_6) except when included in Schedule 5.
IMIDACLOPRID **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 5 per cent or less of imidacloprid.
IMIDOCARB.
IMINOCTADINE TRIALBESILATE.

SCHEDULE 6–continued
IMIPROTHRIN **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 10 per cent or less of imiprothrin.
INDOXACARB (Includes the R and S enantiomers) **except** when included in Schedule 5.
IODINE (excluding its salts, derivatives and iodophors) **except**:
(a)when included in Schedule 2; or
(b)in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.
IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.
3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except:**
(a)when included in Schedule 5; or
(b)in aqueous preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate.
IOXYNIL.
IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except**:
(a)when included in Schedule 5;
(b)in liquid or gel preparations containing 0.1 per cent or less of iron; or
(c)in animal feeds or feed premixes.
ISOCONAZOLE for external treatment of animals.
ISOCYANATES, free organic, boiling below 300° C, **except** in:
(a)viscous polyurethane adhesives; or
(b)viscous polyurethane sealants;
containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

SCHEDULE 6–continued

ISOEUGENOL **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 10 per cent or less of isoeugenol.
LAMBDA-CYHALOTHRIN:
(a)in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or
(b)in other preparations containing 1 per cent or less of lambda-cyhalothrin, **except** when included in Schedule 5.
LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.
LAURYLISOQUINOLINIUM BROMIDE.
†LEAD COMPOUNDS **except**:
(a)when included in Schedule 4 or 5;
(b)in paints, tinters, inks or ink additives;
(c)in preparations for cosmetic use containing 100 mg/kg or less of lead;
(d)in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or
(e)in ceramic glazes when labelled with the warning statement:
CAUTION - Harmful if swallowed. Do not use on surfaces which contact food or drink.written in letters not less than 1.5 mm in height.
LEVAMISOLE for the treatment of animals **except**:
(a)when included in Schedule 4 or 5; or
(b)in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.
LINDANE **except** when included in Schedule 2, 4 or 5.

SCHEDULE 6–continued

MAFENIDE when packed and labelled for the treatment of ornamental fish only.
MALATHION **except**:
(a)when included in Schedule 5;
(b)for human therapeutic use; or
(c)in dust preparations containing 2 per cent or less of malathion.
MCPA **except** when included in Schedule 5.
MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.
MECOPROP **except** when included in Schedule 5.
MECOPROP-P. MEFLUIDIDE.
MELALEUCA OIL (tea tree oil) **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN;
(d)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(e)in preparations containing 25 per cent or less of melaleuca oil.

SCHEDULE 6–continued

MELENGESTROL ACETATE when used as an animal feed additive.
MENAZON.
2-MERCAPTOETHANOL in preparations for use as insect lures.
MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.
MERCUROCHROME for the treatment of animals, in preparations for topical use.
METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.
METALAXYL **except** when included in Schedule 5.
METALDEHYDE **except** when included in Schedule 5.
METHACRIFOS in preparations containing 60 per cent or less of methacrifos.
METHAM.
METHANOL (excluding its derivatives) **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 2 per cent or less of methanol.
METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.
METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.
METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bisthiocyanate.
METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.
METHYL ISOTHIOCYANATE.

SCHEDULE 6–continued

†METHYL METHACRYLATE (excluding its derivatives) **except**:
(a)for cosmetic use; or
(b)in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.
METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.
METHYLNORBORNYLPYRIDINE.
N-METHYL-2-PYRROLIDONE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 25 per cent or less of designated solvents.
METHYL SALICYLATE **except**:
(a)when included in Schedule 5;
(b)in preparations for therapeutic use; or
(c)in preparations containing 5 per cent or less of methyl salicylate.
METOSULAM.
METRIBUZIN.
MICONAZOLE for the external treatment of animals.
MILBEMECTIN **except** when included in Schedule 5.
MONENSIN:
(a)in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or
(b)in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.
MORANTEL **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 10 per cent or less of morantel.

SCHEDULE 6–continued

MOXIDECTIN for external use:
(a)in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or
(b)in preparations containing 2 per cent or less of moxidectin for the treatment of animals,
except when included in Schedule 5.
MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA. NALED **except** when included in Schedule 5.
NAPHTHALENE (excluding its derivatives).
NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos. NARASIN in animal feed premixes containing 12 per cent or less of narasin. NETOBIMIN for the treatment of animals **except** when included in Schedule 5. NICKEL SULFATE.
NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.
NIMIDANE in preparations containing 25 per cent or less of nimidane.
NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 0.5 per cent or less of nitric acid (HNO_3).
NITROBENZENE **except**:
(a)in solid or semi-solid polishes;
(b)in soaps containing 1 per cent or less of nitrobenzene; or
(c)in other preparations containing 0.1 per cent or less of nitrobenzene.

SCHEDULE 6–continued

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.
NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.
NITROXYNIL.
NONOXINOL 9 **except**:
(a)when included in Schedule 5;
(b)in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:
IRRITANT; and
Avoid contact with eyes;
(c)in preparations containing 12.5 per cent or less of nonoxinol 9; or
(d)in preparations for human use.
1-OCTEN-3-OL **except** in preparations containing 5 per cent or less of 1-octen-3-ol.
OCTHILINONE **except** in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.
N-(N-OCTYL)-2-PYRROLIDONE **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 25 per cent or less of designated solvents.
OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquindox.
N-OLEYL-1,3-DIAMINOPROPANE.
OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.
OXADIAZON.
OXALIC ACID **except** its derivatives and insoluble salts.
OXYCLOZANIDE.

SCHEDULE 6–continued

PAECILOMYCES LILACINUS STRAIN 251.
† PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:
(a)for human therapeutic use;
(b)in oral hygiene preparations;
(c)in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d)in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:
PROTECT CUTICLES WITH GREASE OR OIL;
(e)in all other cosmetic preparations; or
(f)in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:
CONTAINS FORMALDEHYDE.
PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.
PARBENDAZOLE.
PEBULATE.
PENNYROYAL OIL **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(c)in preparations containing 4 per cent or less of d-pulegone.

SCHEDULE 6–continued
PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.
PERACETIC ACID **except** when included in Schedule 5.
PERFLUIDONE.
PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.
PERMETHRIN **except**:
(a)when included in Schedule 4 or 5;
(b)in preparations for human therapeutic use containing 5 per cent or less of permethrin; or
(c)in preparations containing 2 per cent or less of permethrin.
PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:
(a)when separately specified in these Schedules;
(b)when included in Schedule 5; or
(c)in preparations containing 3 per cent or less of such substances.
PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.
† PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:
(a)in preparations packed and labelled for photographic purposes;
(b)in preparations packed and labelled for testing water **except** tablets

containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;
(c)in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and

SCHEDULE 6–continued

WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
(d)in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height. PHOSALONE.
PHOSMET.
PHOSPHORIC ACID (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5;
(b)in preparations containing 15 per cent or less of phosphoric acid (H_3PO_4);
(c)in solid or semi-solid preparations; or
(d)in professional dental kits.
PHOXIM.
ortho-PHTHALALDEHYDE **except** when included in Schedule 5. PINDONE.
PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5. PINOXADEN **except** when included in Schedule 5.
PIPEROPHOS.
PIRIMICARB **except** when included in Schedule 5.

SCHEDULE 6–continued

PIRIMIPHOS-ETHYL.
PIRIMIPHOS-METHYL.
POLIXETONIUM SALTS **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 1 per cent or less of polixetonium salts.
POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.
POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.
POTASSIUM CYANATE.
POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5; or

(b)preparations containing 5 per cent or less of potassium hydroxide being:
(i)solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
(ii)liquid or semi-solid preparations the pH of which is 11.5 or less.
POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:
(a)when included in Schedule 5;
(b)in preparations containing 0.5 per cent or less of potassium nitrite;
(c)when present as an excipient in preparations for therapeutic use; or
(d)in aerosols containing 2 per cent or less of potassium nitrite.
POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:
(a)when included in Schedule 5;
(b)in solid orthodontic device cleaning preparations, the pH of which as an "in-use" aqueous solution is 2.5 or more, but not more than 11.5; or

SCHEDULE 6–continued
(c)in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:
(i)solid preparations the pH of which in a 10 g/L aqueous solution is 2.5 or more; or
(ii)liquid or semi-solid preparations the pH of which is 2.5 or more.
POTASSIUM PERSULFATE in hair preparations.
PRALLETHRIN (cis:trans=20:80) **except**:
(a)when included in Schedule 5; or
(b)in insecticidal mats containing 1 per cent or less of prallethrin.
PROCHLORAZ.
PROFENOFOS.
PROMACYL.
PROPACHLOR.
PROPARGITE.
PROPETAMPHOS.
PROPICONAZOLE **except** when included in Schedule 5.
PROPINEB.
PROPIONIC ACID (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5;
(b)in preparations containing 30 per cent or less of propionic acid; or
(c)for therapeutic use.
PROPOXUR **except** when included in Schedule 5.
PROSULFOCARB.
PROTHIOFOS.
d-PULEGONE **except** in preparations containing 4 per cent or less of d-pulegone.

SCHEDULE 6–continued
PYRACLOFOS.
PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.
PYRIDALYL.
PYRIDATE.
PYRIPROLE.
PYRITHIONE COPPER.
PYRITHIONE ZINC **except**:
(a)when included in Schedule 2 or 5;
(b)for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(c)in semi-solid hair preparations for animal use;
(d)in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statement "Keep out of eyes" and "If in eyes rinse well with water";
(e)when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or
(f)in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.
PYROXSULAM.
QUATERNARY AMMONIUM COMPOUNDS **except**:
(a)when separately specified in these Schedules;
(b)when included in Schedule 5;
(c)dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or
(d)in preparations containing 5 per cent or less of such quaternary ammonium compounds.

SCHEDULE 6–continued

QUIZALOFOP ETHYL.
QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.
QUIZALOFOP-P-TEFURYL.
RESMETHRIN **except** when included in Schedule 5.
ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.
†SAFROLE **except**:
(a)for internal use; or
(b)in other preparations containing 1 per cent or less of safrole. SAGE OIL (Dalmatian) **except**:
(a)in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child- resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;
(b)in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a

restricted flow insert and a child-resistant closure and labelled with the warnings:
KEEP OUT OF REACH OF CHILDREN; and NOT TO BE TAKEN; or
(c)in preparations containing 4 per cent or less of thujone.
SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.
SASSAFRAS OIL **except**:
(a)for internal use; or
(b)in other preparations containing 1 per cent or less of safrole.

SCHEDULE 6–continued

SELENIUM:
(a)in preparations containing 2.5 per cent or less of selenium when packed and labelled:
(i)for the blueing of gun barrels;
(ii)for photographic purposes; or
(iii)for the colouring of lead or lead alloys;
(b)in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or
(c)for the treatment of animals:
(i)in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;
(ii)in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;
(iii)in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than
0.25 mg/day; or
(iv)as barium selenate in preparations for injection containing 5 per cent or less of selenium.
SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.
SILICOFLUORIDES except:
(a)when included in Schedule 5; or
(b)in preparations containing 15 mg/kg or less of fluoride ion.
SILVER NITRATE **except**:
(a)when included in or expressly excluded from Schedule 2; or
(b)in preparations containing 1 per cent or less of silver.

SCHEDULE 6–continued

SINBIOALLETHRIN **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 1 per cent or less of sinbioallethrin.
SODIUM ALUMINATE (excluding its salts and derivatives) **except**:
(a)in solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b)in liquid preparations the pH of which is 11.5 or less.
SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.
SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:
(a)when included in Schedule 5; or
(b)preparations containing 5 per cent or less of sodium hydroxide being:
(i)solid preparations the pH of which in a 10 g/L aqueous solution is 11.5 or less; or
(ii)liquid or semi-solid preparations the pH of which is 11.5 or less.
SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:
(a)when included in Schedule 2 or 5;
(b)in preparations containing 0.5 per cent or less of sodium nitrite;
(c)when present as an excipient in preparations for therapeutic use; or
(d)in aerosols containing 2 per cent or less of sodium nitrite.
SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:
(a)when included in Schedule 5; or
(b)in preparations containing 15 per cent or less of sodium percarbonate. SODIUM PERSULFATE
(a)in hair preparations; or
(b)in products for the treatment of water for swimming pools and spas.

SCHEDULE 6–continued

SODIUM SULFIDE in preparations for use as insect lures.
SPIROTETRAMAT.
SPIROXAMINE.
SULCOFURON in preparations for the treatment of carpets during manufacture.
SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.
SULFLURAMID.
SULFURIC ACID (excluding its salts and derivatives) **except**:
(a)in fire extinguishers; or
(b)in preparations containing 0.5 per cent or less of sulfuric acid (H_2SO_4). **SULFURYL FLUORIDE**.
SULPROFOS. 2,4,5-T.
N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.
TAR ACIDS distilling within the range 230 -290°C inclusive.
TCMTB (2-[thiocyanomethylthio]benzothiazole).
TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5. TEBUFENPYRAD.
TEBUTHIURON.
TEMEPHOS **except** when in Schedule 5.
TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of terbuthylazine. TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

SCHEDULE 6–continued
TETRACHLOROETHYLENE **except**:
(a)when included in Schedule 2 or 5;
(b)in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or
(c)in preparations for the treatment of animals.
TETRACONAZOLE **except** when included in Schedule 5.
TETRADIFON.
2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2',6,6'-tetraisopropyl-diphenyl-carbodiimide.
TETRAMISOLE in preparations for the treatment of animals.
THIACLOPRID.
THIAMETHOXAM **except** when included in Schedule 5.
THIAZA**FLU**RON.
THIODICARB **except** when included in Schedule 5.
THIOMETON.
THIOUREA and ALKYL THIOUREAS **except**:
(a)when separately specified in these Schedules; or
(b)for therapeutic use.
THIRAM **except** in paint containing 0.5 per cent or less of thiram. THUJONE **except** in preparations containing 4 per cent or less of thujone.
TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.
†TOLUENEDIAMINE not elsewhere specified in these Schedules:
(a)in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:
KEEP OUT OF REACH OF CHILDREN, and

SCHEDULE 6–continued
WARNING - This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.
written in letters not less than 1.5 mm in height; or
(b)in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:
WARNING - This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.
written in letters not less than 1.5 mm in height.
TOLYLFLUANID.
TRANSFLUTHRIN except:

(a)in preparations containing 1 per cent or less of transfluthrin; or
(b)in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.
TRIADIMEFON **except**:
(a)when included in Schedule 5; or
(b)in fertilisers containing 5 g/kg or less of triadimefon.
TRICHLORFON **except** metrifonate included in Schedule 4.
TRICHLOROACETIC ACID **except**:
(a)when included in Schedule 4 or 5; or
(b)in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.
TRICHLOROETHYLENE **except** when included in Schedule 4.
TRICHLOROPHENOL.
TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

SCHEDULE 6–continued

TRICLOPYR.
TRIDEMORPH.
TRIETHYL PHOSPHATE.
TRIFLUOROMETHANESULFONIC ACID.
TRINITROPHENOL (excluding its derivatives) **except**:
(a)in preparations for human therapeutic use; or
(b)in preparations containing 5 per cent or less of trinitrophenol.
TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.
VAMIDOTHION.
WARFARIN **except** when included in Schedule 4 or 5.
XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.
ZERANOL in ear implants for use as a growth promotant in steer cattle.
ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.
ZINC CHLORIDE **except**:
(a)when included in Schedule 2; or
(b)in preparations containing 5 per cent or less of zinc chloride.
ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.
ZINC SULFATE **except**:
(a)when included in or expressly excluded from Schedule 4; or
(b)in other preparations containing 5 per cent or less of zinc sulfate.
ZIRAM in granular preparations.

SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.
ACIBENZOLAR-S-METHYL.
ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.
ACRYLONITRILE.
ALACHLOR.
ALDICARB.
ALDOXYCARB.
ALLYL ALCOHOL.
ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.
AMINACRINE for veterinary use **except** when included in Schedule 5.
AMINOCARB **except** when included in Schedule 6. 4-AMINOPYRIDINE **except** when included in Schedule 4.
AMITON.
ARPRINOCID.
ARSENIC **except**:
(a)when separately specified in this Schedule;
(b)when included in Schedule 4 or 6;
(c)as selenium arsenide in photocopier drums;
(d)as 10,10'-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;
(e)as 10,10'-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other than when included in articles:
(i)in contact with food stuffs, animal feeds or potable water;
(ii)of clothing and footwear in contact with the skin;

SCHEDULE 7–continued

(iii)used as infant wear; or
(iv)intended for use as packaging materials;
(f)in animal feeds containing 75 g/tonne or less of arsenic; or
(g)in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.
AZAFENIDIN.
AZINPHOS-ETHYL.
AZINPHOS-METHYL.
AZOCYCLOTIN.
BENDIOCARB **except** when included in Schedule 5 or 6.
BENOMYL **except** in paints containing 0.5 per cent or less of benomyl.
BENZENE (excluding its derivatives) **except**:
(a)preparations containing 15 mL/L or less of benzene; or
(b)petrol containing 50 mL/L or less of benzene. BETACY**FLU**THRIN **except** when included in Schedule 5 or 6.
BIFENTHRIN **except**:
(a)when included in Schedule 6; or
(b)in preparations containing 0.5 per cent or less of bifenthrin.
BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.
BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.
BROMADIOLONE **except** when included in Schedule 6.
BROMETHALIN **except** when included in Schedule 6.
BROMINE (excluding its salts and derivatives).

SCHEDULE 7–continued

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant. CACODYLIC ACID **except**:
(a)when included in Schedule 6; or
(b)in animal feeds containing 75 g/tonne or less of arsenic. CADUSAFOS **except** when included in Schedule 6.
CALCIFEROL for use as a rodenticide **except** when included in Schedule 6. CAPTAFOL.
CARBADOX.
CARBOFURAN.
CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.
CARBOPHENOTHION.
CARBOSULFAN.
CHLORDECONE.
CHLORDIMEFORM.
CHLORFENAPYR **except** when included in Schedule 6.
CHLORFENVINPHOS.
CHLORINE (excluding its salts and derivatives).
CHLORHEXIDINE **except**:
(a)when included in Schedule 5 or 6;
(b)in preparations containing 1 per cent or less of chlorhexidine; or
(c)when in solid preparations.
CHLOROMETHIURON. 5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

SCHEDULE 7–continued

4-CHLORO-o-TOLUIDINE.
CHLOROPICRIN **except** when included in Schedule 6.
CHLORTHIOPHOS.
COLECALCIFEROL for use as a rodenticide. COUMAPHOS **except** when included in Schedule 6.
COUMATETRALYL **except** when included in Schedule 5 or 6.
CREOSOTE derived from coal.
CREOSOTE derived from beechwood.
CYANIDES, metallic **except**:
(a)ferricyanides;
(b)ferrocyanides; or
(c)when separately specified in these Schedules. CYANOGEN.
CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50. CYHEXATIN.
DELTAMETHRIN **except** when included in Schedule 5 or 6.

DEMETON.
DEMETON-O-METHYL. DEMETON-S-METHYL. DIALIFOS.
4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).
1,2-DIBROMO-3-CHLOROPROPANE.
1,3-DICHLOROPROPENE.
DICHLORVOS **except** when included in Schedule 5 or 6.

SCHEDULE 7–continued

DICROTOPHOS.
DIFENACOUM **except** when included in Schedule 6.
DIFETHIALONE **except** when included in Schedule 6.
DIMEFOX.
4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine). DIMETHYL SULFATE.
DIMETILAN.
DINITROCRESOLS **except** when included in Schedule 4 or 6.
DINITROPHENOLS **except** when included in Schedule 4 or 6.
DINOCAP.
DINOSEB.
DIQUAT **except** when included in Schedule 6.
DISULFOTON **except** when included in Schedule 6.
DORAMECTIN **except** when included in Schedule 5 or 6.
DSMA **except** when included in Schedule 6.
EMAMECTIN **except** when included in Schedule 5 or 6.
ENDOSULFAN **except** when included in Schedule 6.
ENDOTHAL **except** when included in Schedule 6.
ENDRIN.
EPICHLOROHYDRIN.
EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use. EPRINOMECTIN **except** when included in Schedule 5.
ETACONAZOLE.
ETHION.

SCHEDULE 7–continued

ETHOPROPHOS **except** when included in Schedule 6. ETHYLENE DIBROMIDE.
ETHYLENE OXIDE.
FAMPHUR **except** when included in Schedule 6. FENAMIPHOS **except** when included in Schedule 6. FENOXACRIM **except**:
(a)when included in Schedule 6; or
(b)in treated carpets. FENSULFOTHION.
FENTHION **except** when included in Schedule 5 or 6. FENTHION-ETHYL.
FLOCOUMAFEN **except** when included in Schedule 6.
FLUCOFURON except:
(a)when included in Schedule 6; or

(b)in treated carpets. FLUCYTHRINATE. FLUMIOXAZIN. FLUOROACETAMIDE. FLUOROACETIC ACID. FOLPET.

FORMETANATE.

FURATHIOCARB **except** when included in Schedule 5. GAMMA-CYHALOTHRIN **except** when included in Schedule 5. HALOFUGINONE **except** when included in Schedule 4.

SCHEDULE 7–continued

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any fraction of which boils above 350°C **except**:

(a)when in solid polymers;

(b)when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or

(c)when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

(a)when included in Schedule 4; or

(b)its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) except when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

SCHEDULE 7–continued

MADURAMICIN **except**:

(a)when included in Schedule 5; or

(b)in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a)when separately specified in this Schedule;
(b)when included in Schedule 2, 4 or 6;
(c)in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;
(d)mercury (metallic) in scientific instruments;
(e)dental amalgams; or

(f)in a sealed device, for therapeutic use, which prevents access to the mercury. METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6. METHOMYL **except** when included in Schedule 6. METHOXYETHYLMERCURIC ACETATE.

SCHEDULE 7–continued

METHOXYETHYLMERCURIC CHLORIDE.
METHYL BROMIDE.
METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL **except**:
(a)when included in Schedule 6;
(b)when used in laboratory analysis; or
(c)when packed for industrial use in containers with a nominal capacity of 100 L or more.
4,4'-METHYLENEBIS[2-CHLOROANILINE] (MOCA).
METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5. MEVINPHOS.
MIPAFOX.
MIREX.
MOLINATE.
MONOCROTOPHOS.
MOXIDECTIN **except** when included in Schedule 4, 5 or 6.
MSMA **except** when included in Schedule 6.
NAPHTHALOPHOS **except** when included in Schedule 6.
NICOTINE **except**:
(a)when included in Schedule 6;
(b)in preparations for human therapeutic use; or

(c)in tobacco prepared and packed for smoking. NIMIDANE **except** when included in Schedule 6. NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

SCHEDULE 7–continued

OMETHOATE **except** when included in Schedule 5 or 6.
OXAMYL.
OXYDEMETON METHYL.

PARAQUAT.
PARATHION.
PARATHION-METHYL **except** when included in Schedule 6.
PENTACHLOROPHENOL **except** when included in Schedule 6.
PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.
PHORATE.
PHOSFOLAN.
PHOSPHIDES, METALLIC.
PHOSPHINE.
PHOSPHORUS, YELLOW (excluding its salts and derivatives).
POTASSIUM NITRITE **except**:
(a)when included in Schedule 5 or 6;
(b)in preparations containing 0.5 per cent or less of potassium nitrite;
(c)when present as an excipient in preparations for therapeutic use; or
(d)in aerosols containing 2 per cent or less of potassium nitrite. PROCYMIDONE.
PROPYLENE OXIDE. PYRINURON.
QUININE for veterinary use **except** when included in Schedule 5. SCHRADAN.

SCHEDULE 7–continued

SELENIUM **except**:
(a)when included in Schedule 6;
(b)as selenium arsenide in photocopier drums;
(c)in preparations for therapeutic use other than:
(i)drench concentrates containing 2.5 per cent or less of selenium; or
(ii)pour-on preparations containing 0.5 per cent or less of selenium;
(d)in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or
(e)in fertilisers containing 200 g/tonne or less of selenium.
SEMDURAMICIN **except**:
(a)when included in Schedule 6; or
(b)in animal feeds containing 25 mg/kg or less of antibiotic substances.
SODIUM NITRITE **except**:
(a)when included in Schedule 2, 5 or 6;
(b)in preparations containing 0.5 per cent or less of sodium nitrite;
(c)when present as an excipient in preparations for therapeutic use; or
(d)in aerosols containing 2 per cent or less of sodium nitrite. STRYCHNINE **except** when included in Schedule 4.
SULCOFURON **except**:
(a)when included in Schedule 6; or
(b)in treated carpets. SULFENTRAZONE. SULFOTEP.
TEFLUTHRIN **except** when included in Schedule 5.

SCHEDULE 7–continued

TEPP.
TERBUFOS.
TETRACHLOROETHANE.
2,2',6,6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.
THALLIUM.
THIOFANOX.
TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:
(a)when separately specified in this Schedule;
(b)in plastics;
(c)in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or
(d)in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.
ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.
TRIAMIPHOS.
TRIAZBUTIL.
TRIBUFOS (S,S,S-tributylphosphorotrithioate).
VINCLOZOLIN.
VINYL CHLORIDE.
ZETA-CYPERMETHRIN **except** when included in Schedule 6.
ZIRAM **except** when included in Schedule 6.

SCHEDULE 8

(Substances marked # are subject to additional controls - see Appendix D)
ACETYLDIHYDROCODEINE.
ACETYLMETHADOL.
ACETYLMORPHINES.
ALFENTANIL.
ALPHACETYLMETHADOL.
ALPHAPRODINE.
AMPHETAMINE.
AMYLOBARBITONE **except** when included in Schedule 4.
ANILERIDINE.
BENZYLMORPHINE.
BEZITRAMIDE.
BUPRENORPHINE.
BUTOBARBITONE.
BUTORPHANOL.
CARFENTANYL.
COCAINE.
CODEINE **except** when included in Schedule 2, 3 or 4.
CODEINE-N-OXIDE.
CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).
CYCLOBARBITONE.

SCHEDULE 8–continued
DEXAMPHETAMINE.
DEXTROMORAMIDE.
DEXTROPROPOXYPHENE **except** when included in Schedule 4.
DIFENOXIN **except** when included in Schedule 4. DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.
DIHYDROMORPHINE.
DIPHENOXYLATE **except** when included in Schedule 3 or 4. DIPIPANONE.
DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.
DROTEBANOL.
ETHYLAMPHETAMINE.
ETHYLMORPHINE **except** when included in Schedule 2 or 4. FENTANYL.
FLUNITRAZEPAM.
HYDROCODONE.
HYDROMORPHINOL.
HYDROMORPHONE.
KETAMINE.
LEVAMPHETAMINE.
LEVOMETHAMPHETAMINE.
LEVOMORAMIDE.
LEVORPHANOL (excluding its stereoisomers).
METHADONE.

SCHEDULE 8–continued
METHYLAMPHETAMINE.
METHYLDIHYDROMORPHINE.
METHYLPHENIDATE.
1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).
MORPHINE.
MORPHINE METHOBROMIDE.
MORPHINE-N-OXIDE.
NABILONE.
NORCODEINE.
NORMETHADONE.
OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.
OXYCODONE.
OXYMORPHONE.
PENTAZOCINE.
PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.
PHENDIMETRAZINE.
PHENMETRAZINE.
PHENOPERIDINE.
4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).
PHOLCODINE **except** when included in Schedule 2 or 4.
PIRITRAMIDE.

SCHEDULE 8–continued

PROPIRAM.
QUINALBARBITONE.
RACEMORAMIDE.
REMIFENTANIL.
SECBUTOBARBITONE.
SUFENTANIL.
THEBACON.
THEBAINE.
TILIDINE.

SCHEDULE 9

(Trivial or unofficial names are marked *)
ACETORPHINE.
ACETYL-ALPHA-METHYLFENTANYL.
ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these Schedules.
ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.
ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these Schedules.
ALLYLPRODINE.
ALPHAMEPRODINE.
ALPHA-METHYLFENTANYL.
ALPHA-METHYLTHIOFENTANYL.
ALPHAMETHADOL.
2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE *(STP or DOM).
5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these Schedules.
BENZETHIDINE.
BENZYLPIPERAZINE *(BZP).
BETACETYLMETHADOL.
BETA-HYDROXYFENTANYL.
BETA-HYDROXY-3-METHYLFENTANYL.
BETAMEPRODINE.
BETAMETHADOL.

BETAPRODINE.

SCHEDULE 9–continued
4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE *(BDMPEA).
BUFOTENINE.
CANNABIS **except**:
(a)when separately specified in these Schedules; or
(b)processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.
CATHINONE.
CLONITAZENE.
COCA LEAF.
CODOXIME.
4-CYANO-2-DIMETHYLAMINO-4,4'-DIPHENYLBUTANE.
DESOMORPHINE.
DIAMPROMIDE.
DIETHYLTHIAMBUTENE.
N,N-DIETHYLTRYPTAMINE *(DET).
DIMENOXADOL.
DIMEPHEPTANOL. 2,5-DIMETHOXYAMPHETAMINE *(DMA).
2,5-DIMETHOXY-4-BROMOAMPHETAMINE *(DOB). 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE *(DOET). 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE *(2C-T-2). 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE *(2C-I). 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE *(2C-T-7). 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE *(PSILOCINE or PSILOTSIN).

SCHEDULE 9–continued
3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL- 6H-DIBENZO (b,d) PYRAN *(DMHP).
N, -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE *(MDMA).
N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).
DIMETHYLTHIAMBUTENE.
N,N-DIMETHYLTRYPTAMINE *(DMT).
DIOXAPHETYL BUTYRATE.
ECGONINE.
N-ETHYL- -METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE *(N-ETHYL MDA).
ETHYLMETHYLTHIAMBUTENE.
ETICYCLIDINE *(PCE).
ETONITAZENE.
ETORPHINE.
ETOXERIDINE.
FENETYLLINE.

FURETHIDINE.
HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:
(a)containing 0.1 per cent or less of harmala alkaloids; or
(b)in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.
HEROIN.
3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN *(PARAHEXYL).
4-HYDROXYBUTANOIC ACID and its salts. HYDROXYPETHIDINE.

SCHEDULE 9–continued

ISOMETHADONE.
KETOBEMIDONE.
LEVOMETHORPHAN (excluding its stereoisomers).
LEVOPHENACYLMORPHAN.
LYSERGIC ACID.
LYSERGIDE.
MECLOQUALONE.
METAZOCINE.
METHAQUALONE.
METHCATHINONE.
5-METHOXY- -METHYLTRYPTAMINE *(5-MeO-AMT).
5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE *(MMDA).
4-METHOXY- -METHYLPHENYLETHYLAMINE *(PMA).
METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10- DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7- CARBOXYLATE *(SALVINORIN A).
4-METHYLAMINOREX.
METHYLDESORPHINE.
3,4-METHYLENEDIOXYAMPHETAMINE *(MDA).
3-METHYLFENTANYL.
N- -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE *(N-HYDROXY MDA).
N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE *(MBDB).
2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).
1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE *(MPPP).

SCHEDULE 9–continued

4-METHYLTHIOAMPHETAMINE.
3-METHYLTHIOFENTANYL. METOPON.
MITRAGYNA SPECIOSA.
MITRAGYNINE.

MORPHERIDINE.
MUSCIMOL.
MYROPHINE.
NICOCODINE.
NICODICODINE.
NICOMORPHINE.
NORACYMETHADOL.
NORLEVORPHANOL.
NORMORPHINE.
NORPIPANONE.
PARA-**FLUO**ROFENTANYL.
PHENADOXONE.
PHENAMPROMIDE.
PHENAZOCINE.
PHENCYCLIDINE *(PCP).
PHENOMORPHAN.
1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE *(PEPAP).
PIMINODINE.
PROHEPTAZINE.

SCHEDULE 9–continued
PROPERIDINE.
PSILOCYBINE.
RACEMETHORPHAN.
RACEMORPHAN.
ROLICYCLIDINE *(PHP or PCPY).
SALVIA DIVINORUM.
TENOCYCLIDINE *(TCP).
TETRAHYDROCANNABINOLS and their alkyl homologues **except**:
(a)when separately specified in this Schedule;
(b)when included in Schedule 8;
(c)in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:
Not for internal use; or Not to be taken; or
(d)in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.
THIOFENTANYL.
1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE *(TFMPP).
TRIMEPERIDINE.
3,4,5-TRIMETHOXY- -METHYLPHENYLETHYLAMINE *(TMA).
3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) and other substances structurally derived from methoxy-phenylethylamine **except**:
(a)methoxyphenamine; or
(b)where separately specified in this Schedule. 1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

PART 5 - APPENDICES

APPENDIX A
GENERAL EXEMPTIONS

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS:

(a)toy, when complying with the requirements of Australian Standard AS 8124.4-2003 *Safety of toys - Part 4: Experimental sets for chemistry and related activities*; or

(b)for educational use, containing Schedule 5 or 6 poisons I containers of 3 mL or less of each liquid preparation or 5 g or less of each solid preparation in a discrete unit.

COPPER COMPOUNDS in paints.

DEXTRANS, GELATIN - SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes/blood volume expanders.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

(a)food additives before incorporation into food; or

(b)when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

APPENDIX A–continued

HUMAN BLOOD PRODUCTS including:

(a)whole blood;

(b)blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and

(c)the following plasma-derived therapeutic proteins and their equivalent recombinant alternatives:

(i)albumin;

(ii)anticoagulation complex;

(iii)clotting factors;

(iv)fibrinogen;

(v)protein C;
(vi)prothrombin complex concentrate (PCC); and
(vii)thrombin.
IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.
INTRAOCULAR VISCOELASTIC PRODUCTS.
LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.
MATCHES.
MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS.
MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, as in force from time to time, **except**:
(a)injectable tissue reconstructive, augmentation and restoration materials, including collagen;
(b)medical devices which include anticoagulants;
(c)artificial tears;

APPENDIX A–continued

(d)urinary catheters; or
(e)intra-articular fluids.
MOTOR, HEATING or FURNACE FUELS **except**:
(a)when the contrary intention appears in any Schedule;
(b)when containing methanol;
(c)toy or hobby fuels; or
(d)petrol or kerosene when packed in containers having a capacity of 20 litres or less.
NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.
PAPER **except**:
(a)when prepared for pesticidal use; or
(b)when containing a poison included in Schedule 8 or 9.
PHOTOGRAPHIC PAPER or FILM.
PIGMENTS when immobilised in a polymer. PORCELAIN.
PRINTING INKS or INK ADDITIVES **except**:
(a)when containing a pesticide; or
(b)preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.
RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.
RADIOISOTOPES for therapeutic use.
SEEDS treated with seed protectants.
SINGLE-USE TUBES for the estimation of alcohol content of breath.

APPENDIX A–continued

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.
VITREOUS ENAMELS.
WRITING CORRECTION pens which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

APPENDIX B
SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL
BY SCHEDULING

[This appendix should be read in conjunction with Appendix A]

INTRODUCTION

At various times, the NDPSC has considered substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary or not the most appropriate means of controlling the risk to public health.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

•The toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;

•The use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or

•The public access was limited such that scheduling was inappropriate or unnecessary.

The list has been developed from current scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

The NDPSC considers applications for scheduling. Applications for entry into Appendix B will not be accepted.

APPENDIX B–continued
PART 1

REASONS FOR ENTRY

aLow Toxicity.
bUse pattern restricts hazard.
c Presentation/packaging restricts hazard.
dIndustrial use only.

PART 2
AREAS OF USE

1.Agricultural
1.1Herbicide
1.2Insecticide
1.2.1Insecticide for codling moth
1.2.2Termiticide
1.3Fungicide
1.3.1On seed fungicide
1.4Bird Repellent
1.5Fertiliser
1.6Plant Growth Regulator
1.7Insect Pheromone
1.8Mushroom Bactericide
1.9Acaricide
1.10Biological control agent
2.Veterinary
2.1For animal use
2.2Treatment of mastitis in cows
2.3Coccidiostat
2.4Feed additive
2.5Antiseptic
2.6Scabicide
2.7Anthelmintic
2.8Vitamin/Mineral
2.9Growth Promotant
2.10Ectoparasiticide

APPENDIX B, Part 2–continued

3.Domestic
3.1Aromatherapy
3.2Food additive
3.3Cosmetic
3.4Human use
3.5Miticide
4.Industrial
4.1Water Treatment
4.2Biological control agent
5.Environmental

5.1Mosquito control
6.Human therapeutic use
6.1Diagnostic agent
6.2Medical device
6.3Antiseptic
6.4Sunscreen
6.5External Use
6.6Laxative
6.7Antiseborrheic
6.8Cytoprotective
6.9Vitamin/Mineral
6.10Eye Drops
7.General
7.1Any use
7.2Excipient
7.3Synergist
7.4Flux
7.5Pesticide
7.6Insect Repellent
7.7Solvent
7.8Disinfectant
7.9Preservative
7.10Antioxidant
7.11Resin Activator/Accelerant
7.12Sweetener Artificial
7.13Food additive

APPENDIX B–continued
PART 3
SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

SUBSTANCE	DATE OF ENTRY	REASON AREA FOR LISTING	OF USE
4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE	Feb 2005	b	1.7
AGROBACTERIUM RADIOBACTER	Nov 1989	a	1
ALCOHOL, DEHYDRATED	Aug 2000	b	6
ALUM	May 1997	a	7.1
ALUMINIUM AMMONIUM SULFATE	May 1997	a	7.1
ALUMINIUM POTASSIUM SULFATE	May 1997	a	7.1
ALUMINIUM SILICATE	Nov 1974	a	7.1

ALUMINIUM tris (ETHYLPHOSPHONATE)	Aug 1986	a	1
AMMONIUM PHOSPHATE	Nov 1974	a	7.1
AMMONIUM THIOSULPHATE	Nov 1974	a	7.1
AMPROLIUM	Jun 1969	a	2.3
AMYL ACETATE	Nov 1974	a	7.1
-AMYLASE derived from Aspergillus niger	Feb 2005	a	2.4
ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEA DEXTRAN ADJUNCT	Jun 2004	a	2.1
ASPARTIC ACID	-	a	6
ASULAM	May 1986	a	1
AZIMSULFURON	Jun 2003	a	1.1
BACILLUS SPHAERICUS STRAIN 2362	Feb 2003	a	5.1
BACILLUS THURINGIENSIS	May 1992	a	5.1
(excluding endotoxin)	Jun 2003	a	2.10
BACILLUS TOYOI	Aug 1980	a	2.9
BACULOVIRUS CYDIA POMONELLA	Jun 2006	a	1.2
BENFLURALIN	-	a	1.1
BENSULFURON-METHYL	Aug 1987	a	1
BENTONITE	Jun 2002	a	7.1
BENZYL BENZOATE	Aug 1989	a	1.3.4

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
BETAINE HYDROCHLORIDE	Nov 1974	a	7.1
BIFENAZATE	Oct 2002	a	1.9
BISMUTH SUBNITRATE	Nov 1999	b, c	2.1
BIURET	Nov 1974	a	2.4
BOSCALID	June 2003	a	1.3
BOVINE SOMATOTROPHIN	May 1992	a	2
BROMACIL	Aug 1987	a	1
BROMOPROPYLATE	Nov 1994	a	1
BUPIRIMATE	Nov 1990	a	1
BUTAFENACIL	May 2000	a	1
BUTOXYPOLYPROPYLENE GYLCOL	Nov 1974	a	7.7
n-BUTYL BUTYRATE	-	a	7.1
n-BUTYL LACTATE	-	a	7.1
CARBETAMIDE	Aug 1991	a	1
CARBOXIN	Aug 1987	a	1
CARFENTRAZONE-ETHYL	Aug 1998	a	1
CELLULASE derived from			

Aspergillus niger	Feb 2005	a	2.4
CETYL ALCOHOL	Nov 1974	a	7.1
CHAMOMILE OIL	Feb 2000	a	3.1
CHINA CLAY	Nov 1974	a	7.1
CHLORANTRANILIPROLE	Sep 2008	a	1.2
CHLORFLUAZURON	Oct 2005	a	1.2.2
CHLORFLURENOL	Feb 1974	a	1.6
CHLORIDAZON	May 1988	a	1
CHLOROXYLENOLS	Feb 1975	a	7.8
CITRONELLA OIL	Feb 2000	a	7.1
CLARY SAGE OIL	Feb 2000	a	7.1
CLOPIDOL	Nov 1974	d	2.3
COBALT NAPHTHENATE	-	d	7.1
COLOPHONY	Feb 1997	b	7.4
CROSPOVIDONE	Aug 1996	a	2
CULICINOMYCES CLAVOSPORUS	Nov 1982	a	5.1
CYCLAMIC ACID	Nov 1971	a	7.1
CYCLOHEXANE	Nov 1974	a	7.7

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON AREA FOR LISTING	OF USE
CYCLOHEXANOL ACETATE	-	a	7.7
CYROMAZINE	Nov 1980	a	2
DICLAZURIL	Nov 2001	a	2.3
DIETHYL CARBONATE	-	a	7.1
DIFLUFENICAN	**Feb 1987**	**a**	**1**
DIKEGULAC-SODIUM	Mar 1980	a	1.6
DIMETHICONE		a	7.1
DIMETHYL ETHER	Nov 1988	d	4
DIPHENYLAMINE	Feb 1988	a	1
DIPROPYLENE GLYCOL MONOMETHYL ETHER	Nov 1987	a	4
DIURON	Nov 1987	a	1
DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)	Feb 1970	a	7.1
2,2-DPA	Nov 1989	a	1
DROMETRIZOLE TRISILOXANE	Oct 2003	a	6.4
EPSIPRANTEL	Nov 1991	a	2
ETHAMETSULFURON-METHYL	Nov 2000	a	1.1
ETHOPABATE	Jun 1969	d	2.3
ETHYL ACETATE	Nov 1974	a	7.1

ETHYL ALCOHOL	Nov 1974	a	7.1
ETHYLBUTYLACETYL-AMINOPROPRIONATE	Aug 2000	a	3.4
ETHYL BUTYRATE	-	a	7.1
ETHYL LACTATE	-	a	7.1
ETOXAZOLE	Oct 2003	a	1.2
FENFURAM	May 1977	a	1.3.1
FENHEXAMID	Feb 1999	a	1
FENOXYCARB	Feb 1988	a	1
FLUFENOXURON	**Feb 1997**	**a**	**1**
FLUMETSULAM	**Feb 1992**	**a**	**1**
FLUOMETURON	**Aug 1989**	**a**	**1**
FLUTOLANIL	**Nov 2001**	**a**	**1.3**
FLUROXYPYR	**May 1986**	**a, c**	**1**
FORCHLORFENURON	Feb 2005	a	1.6
FULLERS EARTH	Nov 1974	a	7.1

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON AREA FOR LISTING	OF USE
FUNGAL PROTEASE derived from Aspergillus niger	Feb 2005	a	2.4
GERANIUM OIL	Feb 2000	a	7.1
GIBBERELLIC ACID	Nov 1974	a	1.6
-GLUCANASE derived from Aspergillus niger	Feb 2005	a	2.4
HEXAFLURON	**Nov 1988**	**a**	**1**
HEXYL ACETATE	-	a	7.7
HEXYTHIAZOX	Feb 1988	a	1
HUMAN OSTEOGENIC PROTEIN-1 (OP-1)	Aug 2001	b	6.2
HYDROPRENE	Feb 1988	a	1
HYDROXYPROPYL CELLULOSE	Nov 1982	a	7.1
ICODEXTRIN	Nov 2000	b	6
INDOLE-3-ACETIC ACID	Feb 1985	b	1.6
ISOPRENE ALCOHOL	-	a	7.1
IPRODIONE	Feb 1997	a	1
ISOSTEARYL ALCOHOL ETHOXYLATE	Nov 1999	a	5.1
KAOLIN	Nov 1974	a	7.1
KRESOXIM-METHYL	Aug 1999	a	1
KUNZEA OIL	Feb 2000	a	7.1
LAURIC ACID	Oct 2005	a	7.1
LAURYL ALCOHOL (1-DODECANOL)	Nov 1974	a	7.1
LAVANDIN OIL	Feb 2000	a	7.1

LAVENDER OIL	Feb 2000	a	7.1
LEAD, METALLIC	-	a	7.1
LEMONGRASS OIL	Feb 2000	a	7.1
LEPIDOPTEROUS SEX PHEROMONES	Nov 1990	a	1
LIMONENE (DIPENTENE)	Jun 2002	a	7.1
LINOLEIC ACID	Oct 2005	a	7.1
LINSEED FATTY ACIDS	Aug 1990	a	2.1
LINURON	Feb 1990	a	1
LIQUORICE, DEGLYCYRRHISINISED	May 1999	a	7.1
MALEIC HYDRAZIDE	Nov 1992	a	1
MANGANESE DIOXIDE	May 1999	b	1
MESOLSULFURON-METHYL	Feb 2002	a	1.1
METARHIZIUM ANISOPLIAE	Feb 2000	b	4.2

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
METARHIZIUM ANISOPLIAE	Jun 2003	a	1.10
METHOPRENE	Aug 1987	a	1
METHOXYFENOZIDE	Nov 2000	a	1
METHYL ACETATE	-	a	7.7
METHYL BENZOQUATE	Nov 1974	d	2.3
1-METHYLCYCLOPROPENE	Jun 2003	a	1.6
METHYL p-HYDROXYBENZOATE	Nov 1974	a	7.9
METSULFURONMETHYL	Nov 1985	a	1.1
MYRISTIC ACID	Oct 2005	a	7.1
NAPROPAMIDE	Aug 1987	a	1
NAPTHYL ACETAMIDE	Nov 1974	a	1.6
NEROLI OIL	Feb 2000	a	7.1
NICARBAZIN	Jun 1969	d	2.3
NISIN	Jun 2003	a	3.2
NORFLURAZON	**Nov 1983**	**a**	**1.1**
NOVALURON	Nov 2000	a	1
NUCLEAR POLYHEDROSIS VIRUS OF *HELICOVERPA* ARMIGERA OCCLUSION BODIES	Feb 2004	a	1.2
OCTYL ALCOHOLS	Nov 1974	a	7.1
OLEIC ACID	Oct 2005	a	7.1
ORANGE OIL, SWEET	Aug 2000	a	7.1
OXABETRINIL	Feb 1987	a	1
OXYFLUORFEN	**May 2001**	**a**	**1**
PALMAROSA OIL	Feb 2000	a	7.1
PALMITIC ACID	Oct 2005	a	7.1

PATCHOULI OIL	Feb 2000	a	7.1
PECTINASE derived from Aspergillus niger	Feb 2005	a	2.4
PENCYCURON	Aug 1994	a	1
PENTADECANOIC ACID	Oct 2005	a	7.1
PEPPERMINT OIL	Feb 2000	a	7.1
PHENMEDIPHAM	May 1989	a	1.1
d-PHENOTHRIN	Feb 1982	a	7.5, 1.2
PHYTASE	Feb 1996	a	2.4
PICLORAM	Aug 1987	a	1

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
PICOLINAFEN	May 2000	a	1
PIMELIC ACID	Oct 2005	a	7.1
PIPERONYL BUTOXIDE	Aug 1991	a	7.5
POLOXALENE	Nov 1974	a	7.1
POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE (PolyDADMAC)	Nov 1997	a	4.1
POLYHEDROSIS VIRUS OF HELICO ZEA OCCLUSION BODIES	Nov 1996	a	1
POLY (GNRF) OVALBUMIN	Feb 1990	a	2
POLYSORBATE 20	May 2001	a	1
PORCINE SOMATOTROPHIN	Nov 1991	c	2
POTASSIUM SORBATE	Oct 2004	a	1.3
POTASSIUM BICARBONATE	Jun 2004	a	1
PRAZIQUANTEL	Oct 2005	a	2.1
PROPYL ACETATES	-	a	7.1
PROPYLENE GLYCOL	Nov 1974	a	7.1
2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER	Nov 1987	a	4
PROTHIOCONAZOLE	June 2005	a	1.3.1
PSEUDOMONAS **FLUORESCENS**	May 1985	a	1.8
PYRIMETHANIL	Feb 1996	a	1
PYRIPROXYFEN	Aug 1994	a	1
QUASSIA	Nov 1974	d	6, 2.1
QUINOXYFEN	Nov 2001	a	1.3
ROSEMARY OIL	Feb 2000	a	7.1
SAGE OIL (Spanish)	Feb 2000	a	7.1
SANDALWOOD OIL	Feb 2000	a	7.1
SEAWEED & UNFRACTIONED SEAWEED			

EXTRACTS	Feb 1985	d	1.5
SIMAZINE	Nov 1987	a	1.1
SODIUM BICARBONATE	Jun 2004	a	1
SODIUM PROPIONATE	Oct 2004	a	1.3
STERIC ACID	Oct 2005	a	7.1
SUCRALFATE	Aug 1982	a	6.8
SULESOMAB	Jun 2002	b	6.1

APPENDIX B, Part 3–continued

SUBSTANCE	DATE OF ENTRY	REASON FOR LISTING	AREA OF USE
SULFOSULFURON	Feb 1998	a	1
SULPHATED POLYSACCHARIDES	-	a	7.1
TANNIC ACID	Dec 1965	a	7.1
TANNIC ACID/BENZYL ALCOHOL PRODUCT	Nov 1993	a	7.1
TERBACIL	Aug 1987	a	1
THAUMATIN	Nov 1990	a	3.2
THIDIAZURON	Nov 1989	a	1
TRIASULFURON	Feb 1988	a	1
TRICHODERMA HARZIANUM	May 1996	a	1
(Z)-9-TRICOSENE	Aug 1991	a	1
TRIETHYLENE GLYCOL	Nov 1974	a	7.1
TRIFLOXYSULFURON	Feb 2002	a	1.1
TRIFLURALIN	**Aug 1990**	**a**	**1**
TRIFORINE	Aug 1987	a	1
ULOCLADIUM OUDEMANSII	Oct 2003	a	1.10
UREA	Nov 1974	a	7.1
^{13}C-UREA	May 2001	a	6.1
VETIVER OIL	Feb 2000	a	7.1
VINYL ETHER	Nov 1987	b	6
VITAMIN K	Jul 1963	a	6.9, 2.8
XANTHOPHYLL (lutein)	Nov 1974	a	7.1
XYLANASE derived from Aspergillus niger	Feb 2005	a	2.4
YLANG YLANG OIL	Feb 2000	a	7.1
ZINC NAPHTHENATE	-	a	1.3

Federal Register of Legislative Instruments F2009L03012